 
 Signature [CONTACT_352739]-Time Occlusion Therapy for 
Intermittent Exotropia  in Children  
Funded by: [CONTACT_352703]: IXT7  
Version Number: 1.[ADDRESS_438993], 8th Fl  
[LOCATION_011], MA [ZIP_CODE]  
Phone: 617 -638-4589  
Cell: 617 -735-5688  
Email:[EMAIL_6756]  
Signature/ Date   
Protocol Co-Chair  
Name, degree  Erin C Jenewein, OD, MS, FAAO  
Title  Protocol Co -Chair  
Institution Name  [CONTACT_352740]  
[ADDRESS_438994] Godfrey  
Philadelphia, PA [ZIP_CODE]  
Cell: 920 -456-9105  
Email: [EMAIL_6757]  
Signature/ Date   
JCHR Lead Investigator  
Name, degree  Raymond T. Kraker , M.S.P.H.  
Title  Principal Investigator , PEDIG Director  
Institution Name  [CONTACT_352741]  
[ADDRESS_438995]  
Tampa, FL [ZIP_CODE]  
Phone: 1 -[PHONE_3328]  
Fax: 1 -[PHONE_7287]  
Email: [EMAIL_6758]   
Signature/ Date   
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 2 OF 50 Randomized Trial of Full-Time Occlusion Therapy for 
Intermittent Exotropia in Children  
Funded by: [CONTACT_352703]: IXT7  
Version Number: 1.[ADDRESS_438996], 8th Fl  
[LOCATION_011], MA [ZIP_CODE]  
Phone: [PHONE_7288]  
Cell: 617 -735-5688  
Email:[EMAIL_6756]  
Protocol Co-Chair  
Name, degree  Erin C Jenewein, OD, MS, FAAO  
Title  Protocol Co -Chair  
Institution Name  [CONTACT_352740]  
[ADDRESS_438997] Godfrey  
Philadelphia, PA [ZIP_CODE]  
Cell: [PHONE_7289]  
Email: [EMAIL_6757]  
JCHR Lead Investigator  
Name, degree  Raymond T. Kraker, M.S.P.H.  
Title  Principal Investigator, PEDIG Director  
Institution Name  [CONTACT_352741]  
[ADDRESS_438998]  
Tampa, FL [ZIP_CODE]  
Phone: 1 -[PHONE_3328]  
Fax: 1 -[PHONE_7287]  
Email: [EMAIL_6758]   
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 4 OF 50 TABLE OF CONTENTS  
CHAPTER 1: BACKGROUND INFORMATION  ................................ ................................ .............................  [ADDRESS_438999]  ................................ ................................ .........................  18 
1.4.1 Suppression  ................................ ................................ ................................ ................................ . 18 
1.4.2 Fusional Vergence Amplitudes  ................................ ................................ ................................ ... 18 
1.4.3 Magnitude of Deviation  ................................ ................................ ................................ ...............  18 
1.5 Measuring Patch Wear Time  ................................ ................................ ................................ .............  18 
1.6 Unanswered Questions Regarding Patching Treatment for IXT  ................................ .......................  19 
1.7 Rationale for Present Study  ................................ ................................ ................................ ...............  19 
1.8 Study Objectives  ................................ ................................ ................................ ................................  19 
1.9 Potential Risks and Benefits of Study Treatment  ................................ ................................ ..............  20 
1.9.1 Known Potential Risks  ................................ ................................ ................................ ................  20 
1.9.2 Known Potential Benefits  ................................ ................................ ................................ ............  20 
1.10 Risks of Examination or Testing Procedures  ................................ ................................ ...................  20 
1.11 Risk Assessment  ................................ ................................ ................................ ..............................  20 
1.12 General Considerations ................................ ................................ ................................ ....................  20 
CHAPTER 2: STUDY ENROLLMENT AND RANDOMIZATION  ................................ ................................ .... 21 
2.1 Participant Recruitment and Enrollment  ................................ ................................ ...........................  21 
 Informed Consent  ................................ ................................ ................................ ........................  21 
2.2 Eligibility Criteria  ................................ ................................ ................................ ..............................  21 
 Inclusion Criteria  ................................ ................................ ................................ .........................  21 
 Exclusion Criteria  ................................ ................................ ................................ ........................  23 
2.3 Historical Information  ................................ ................................ ................................ .......................  23 
2.4 Screening and Baseline Procedures  ................................ ................................ ................................ ... 23 
2.5 Randomization  ................................ ................................ ................................ ................................ ... 25 
 Observation Group  ................................ ................................ ................................ ......................  25 
 Full-Time Patching Group  ................................ ................................ ................................ ...........  25 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 5 OF 50 2.6 Monitoring of Adherence  ................................ ................................ ................................ ..................  25 
CHAPTER 3: STUDY FOLLOW -UP ................................ ................................ ................................ ..............  26 
3.1 Study Visits  ................................ ................................ ................................ ................................ ....... 26 
3.2 Phone Call at 4 -weeks  ................................ ................................ ................................ .......................  26 
3.3 Masking Procedures  ................................ ................................ ................................ ..........................  26 
 Masked Examiner  ................................ ................................ ................................ ........................  26 
3.4 Testing Procedures at 3 -Month Outcome Visit  ................................ ................................ .................  26 
3.5 IXT Treatment Changes During Follow -up ................................ ................................ ......................  27 
3.6 Management of Refractive Error During Follow -up ................................ ................................ .........  27 
CHAPTER 4: TESTING PROCEDURES AND QUESTIONNAIRES  ................................ ................................ . 29 
4.1 Clinical Assessments  ................................ ................................ ................................ .........................  29 
CHAPTER 5: UNANTICIPATED PROBLEM AND ADVERSE EVENT REPORTING  ................................ ....... 33 
5.1 Unanticipated Problems  ................................ ................................ ................................ .....................  33 
5.2 Adverse Events  ................................ ................................ ................................ ................................ .. 33 
5.3 Safety Oversight  ................................ ................................ ................................ ................................  33 
5.4 Stoppi[INVESTIGATOR_2121]  ................................ ................................ ................................ ...............................  34 
5.5 Participant Discontinuation of Study Treatment  ................................ ................................ ...............  34 
CHAPTER 6: MISCELLANEOUS CONSIDERATIONS  ................................ ................................ ...................  35 
6.1 Contacts by [CONTACT_352704]  ................................ ..............................  35 
6.2 Pa rticipant Compensation  ................................ ................................ ................................ ..................  35 
6.3 Participant Withdrawal  ................................ ................................ ................................ ......................  35 
6.4 Confidentiality  ................................ ................................ ................................ ................................ ... 35 
CHAPTER 7: STATISTICAL CONSIDERATIONS  ................................ ................................ ..........................  36 
7.1 Statistical and Analytical Plans  ................................ ................................ ................................ .........  36 
7.2 Primary Objective and Hypothesis  ................................ ................................ ................................ .... 36 
7.3 Sample Size  ................................ ................................ ................................ ................................ ....... 36 
7.4 Interim Monitoring  ................................ ................................ ................................ ............................  38 
7.5 Analysis Datasets  ................................ ................................ ................................ ...............................  38 
7.6 Analysis o f the Primary Efficacy Endpoints  ................................ ................................ .....................  38 
 Sensitivity Analyses  ................................ ................................ ................................ ....................  39 
7.7 Analysis of the Secondary Endpoints  ................................ ................................ ................................  39 
 Near Control  ................................ ................................ ................................ ................................  39 
 Angle of Deviation  ................................ ................................ ................................ ......................  40 
 Level of Suppression  ................................ ................................ ................................ ...................  40 
 Proportion with Anomalous Retinal Correspondence  ................................ ................................ . 40 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 6 OF 50 
 Convergence and Divergence Fusional Amplitudes  ................................ ................................ ... 40 
 IXT Symptom Survey Score  ................................ ................................ ................................ ....... 40 
 PedEyeQ Score  ................................ ................................ ................................ ............................  40 
 Binocular Diplopia by [CONTACT_352705]  ................................ ................................ .......................  40 
7.8 Exploratory Analyses  ................................ ................................ ................................ ........................  41 
 Actual Patch Wear Time  ................................ ................................ ................................ .............  41 
 Outcome of Retinal Correspondence Testing  ................................ ................................ ..............  41 
 Subgroup Analysis of Distance Control  ................................ ................................ ......................  42 
7.9 Safety Analyses  ................................ ................................ ................................ ................................ . 42 
 Deterioration  ................................ ................................ ................................ ................................  42 
 Reduction of Distance Visual Acuity  ................................ ................................ ..........................  42 
 Diplopia  ................................ ................................ ................................ ................................ ....... 42 
7.10 Patching Adherence  ................................ ................................ ................................ .........................  42 
7.11 Additio nal Tabulations and Analyses  ................................ ................................ ..............................  42 
CHAPTER 8: DATA COLLECTION AND MONITOR ING ................................ ................................ ..............  43 
8.1 Case Report Forms and Other Data Collection  ................................ ................................ .................  43 
8.2 Study Records Retention  ................................ ................................ ................................ ...................  43 
8.3 Quality Assurance and Monitoring  ................................ ................................ ................................ .... 43 
8.4 Protocol Deviations  ................................ ................................ ................................ ...........................  44 
CHAPTER 9: ETHICS /PROTECTION OF HUMAN PARTICIPANTS  ................................ ..............................  [ADDRESS_439000]  ................................ ................................ ................................ ................................ . 45 
9.2 Institutional Review Boards  ................................ ................................ ................................ ..............  45 
9.3 Informed Consent Process  ................................ ................................ ................................ .................  45 
 Consent Procedures and Documentation  ................................ ................................ .....................  45 
 Participant and Data Confidentiality  ................................ ................................ ...........................  45 
 Future Use of Data ................................ ................................ ................................ .......................  46 
CHAPTER 10: REFERENCES  ................................ ................................ ................................ .......................  [ADDRESS_439001] OF ABBREVIATIONS  
ABBREVIATION  DEFINITION  
∆ Prism diopters  
ANCOVA  Analysis of covariance  
ATS  Amblyopia Treatment Study  
ATS -HOTV  Amblyopia Treatment Study HOTV visual acuity testing protocol  
CI Confidence interval  
CFR  Code of Federal Regulations  
CR Cycloplegic refraction  
CRF  Case report form  
D Diopter  
DHHS  Department of Health and Human Services  
DSMC  Data safety and monitoring committee  
eCRF  Electronic case report form  
E-ETDRS  Electronic Early Treatment of Diabetic Retinopathy Study visual acuity protocol  
EVA  Electronic visual acuity tester  
FDA  Food and Drug Administration  
FDR  False discovery rate  
FT Full-time patching  
GCP  Good clinical practice  
ICH International Council for Harmonisation  
IOD Interocular difference  
IRB Institutional Review Board  
ITT Intention to treat  
IXT Intermittent exotropia  
JCHR  Jaeb Center for Health Research  
logMAR  Logarithm of the minimal angle of resolution  
log sec arc  Logarithm of the seconds of arc  
MCMC  Monte Carlo Markov chain  
NIH National Institutes of Health  
Obs Observation  
PACT  Prism and alternate cover test  
PEDIG  Pediatric Eye Disease Investigator Group  
QA Quality assurance  
QC Quality control  
RBM  Risk-based monitoring  
RCT  Randomized clinical trial  
SAP Statistical analysis pla n 
SD Standard deviation  
SE Spherical equivalent refractive error (Sphere + ½ Cylinder)  
sec arc  Seconds of arc  
SPCT  Simultaneous prism and cover test  
VA Visual acuity  
 
IXT7P ROTV1.0_19A PR2022 PAGE 8 OF 50 PRINCIPAL  INVESTIGATOR  [INVESTIGATOR_352693]-Time Occlusion Therapy for 
Intermittent Exotropia in Children ( IXT7 ) 
Site Number: ________  
 
Each clinical site that is approved to participate in the IXT7  study will have one individual designated as the Protocol 
Principal Investigator (Protocol PI) at the site for that protocol.  This may or may not be the same investigator that 
serves as the overall Site Principal Investigator (Site PI) for all PEDIG studies.   
  
The Protocol PI [INVESTIGATOR_352694] (if different) agrees to the following for the IXT7  study. They will:  
 
• Have a thorough understanding of the protocol design  and study procedures .  
• Ensure that local institutional requirements (if applicable) are satisfied for the protocol and that approvals and 
assurances are obtained annually if required.  
• Ensure that the required protocol -certified staff, facilities, and equipment are available to conduct the 
protocol.  
• Ensure that the required protocol staff have  a thorough understanding of the protocol design and procedures.  
• Provide adequate support and guidance to site investigators, coordinators , and other staff so that the study can 
be conducted according to protocol.  
• Respond promptly to requests from the Coo rdinating Center (CC), Network Chair/s, or Protocol Chair/s.   
• Correspond and maintain accessibility via email and phone with their PEDIG protocol monitor.  
• Oversee local study documentation and records.  
• Conduct periodic meetings of study personnel a t their  site. 
• Cooperate with protocol monitors by [CONTACT_352706], 
study records , protocol binders, clinic charts for study participants, and other necessary records needed for 
on-site or virtual clinic monitori ng visits.  
• Notify the CC if any protocol adherence or data reporting problem is discovered or suspected.  
• Attend scheduled PEDIG meetings and conference calls, including those for any PEDIG committees to which 
appointed.  
• Review study monitoring reports evaluating clinical site performance and discuss with the CC any areas 
identified to be deficient.  
 
The Protocol and PI [INVESTIGATOR_352695] (3) study 
subjects.                                                                                                                                                                                                                                                                                                                                                                                                   
 
In addition to the above, the Protocol PI [INVESTIGATOR_352694] (if different) agree(s) to the following:    
• I/we understand the importance of successful follow -up of participants enrolled at my/our site.  
• I/we agree as a site that we have the potential and commitment to as a site to enroll at least 3 subjects once 
certified.  
 
Protocol Principal Investigator’s Si gnature  Date: _____ / _____ / _____  
 
Name: ____________________________  
 
To be completed only if different:  
 
Site Principal Investigator’s Signature ___________________  _____Date: _____ / _____ / _____  
 
Name: ____________________________  
 
IXT7P ROTV1.0_19A PR2022 PAGE [ADDRESS_439002] is maintained off -
treatment, and how full -time patching compares to other treatment 
strategies.   
Objectives  Determine whether full -time patching is more effective than observation 
for improving distance control of IXT  after 3 months of treatment  (on-
treatment outcome) . 
Study Design  Randomized clinical trial . 
Number of Sites  The study is open to all clinical sites approved to participate in the PEDIG 
network.  
Endpoint  Primary Efficacy Outcome:   
Change in control of IXT at distance after 3 months based upon the 
average of three measures of control at distance.  
Key Safety Outcome s:  
1. Deterioration is defined as meeting one of the following criteria at the 
3 months follow -up visit:  
• Constant  exotropia >= 10Δ at distance AND near  by [CONTACT_225816] . 
Constant  is defined as an exotropia present throughout the 
examination and determined by [CONTACT_352707]/uncover  
tests performed at various times during the exam.  
• Decrease  in near stereoacuity on the Randot Preschool 
Stereotest of at least 2 levels from baseline, or to nil . 
2. Decrease  in distance visual acuity 3 or more logMAR  lines from 
baseline in either eye  or IOD 3 or more logMAR lines . 
3. Diplopia ‘More than 2 times per day’ by [CONTACT_146909]  
4. Diplopia ‘All the Time’ by [CONTACT_352708]:  
Children under the care of a pediatric optometrist or pediatric 
ophthalmologist will be eligible for the study if they meet all the 
following criteria:  
1. Age 3 to < 9 years  
2. IXT meeting all of the following criteria:  
• Intermittent or constant XT at distance (mean distance control 
2.0 or more) with at least 1 control measure of 3, 4 or 5 (i.e., 
indicating spontaneous tropia)  
• Either IXT, exophoria , or orthophoria  at near (cannot have 
control score of 5 on all 3 near assessments)  
• Distance exodeviation between 1 5∆ and 50∆ by [CONTACT_225827]  
• Near exodeviation betwe en 0∆ and 50∆ by [CONTACT_225827]  
• Near exodeviation does not exceed distance by [CONTACT_726] 10∆ 
by [CONTACT_225827]  (convergence insufficiency -type IXT excluded)  
3. Age-normal visual acuity in both eyes:  
• 3 years: 20/50 or better  (>=63 letters)  
• 4 years: 20/40 or better (>=68 letters)  
 
IXT7P ROTV1.0_19A PR2022 PAGE 10 OF 50 PARTICIPANT AREA  DESCRIPTION  
• 5-6 years: 20/32 or better  (>=73 letters)  
• 7-<9 years: 20/25 or better  (>=78 letters)  
4. Interocular difference in distance VA of 2 logMAR lines or less (10 
letters or less on E -ETDRS for patients ≥7 years old). Testing by 
[CONTACT_352709] 3 to < 7 years old and by E -ETDRS for 
participants ≥[ADDRESS_439003] 7 months . 
6. Refractive error between -6.00 D SE and +2.00 D SE (inclusive) 
based on a cycloplegic refraction within [ADDRESS_439004] 2 week s: 
• Myopia > -0.50 D spherical equivalent (SE) in either eye  
• Anisometropia > 1.00 D SE  
• Astigmatism in either eye > 1.00 D  
8. Any refractive correction worn at enrollment (required or not) must 
meet the following guidelines  based on a cycloplegic refraction 
within 7 months : 
• Anisometropia SE must be within 0. 50 D of the full 
anisometropic differ ence correction  
• Astigmatism must be corrected within 0.50 D  
• Axis must be within ±10 degrees if cylinder power is ≤1.00 D and 
within ±5 degrees if cylinder power is >1.00 D.  
• For hyperopia, the spherical component can be reduced at 
investigator discretion provided the reduction is symmetrical  and 
does not meet the definition of deliberate overminus (see below) .  
• For myopia, the intent is to fully correct, but the spherical 
component can be undercorrected at investigator discretion 
provided the re duction is symmetrical and results in no more than 
-0.50 D SE residual (i.e., uncorrected) myopia. Deliberate 
overminus is not allowed.  
• Deliberate overminus is defined for this protocol as a ny refractive 
correction prescribed to yield lenses that are overm inused by 
[CONTACT_726] -0.50D SE than cycloplegic refraction SE  
▪ Less than the full cycloplegic hyperopic correction (i.e., 
prescribing reduced plus) is not considered the same as 
overminusing for this protocol (because most patients 
without IXT but with hyperopic SE refractions up to +2.00 
D SE  would not typi[INVESTIGATOR_352696] a refractive 
correction. ) 
• For refractive errors with an emmetropic or myopic SE , the intent 
is to fully correct, but the spherical component can be 
undercorrected at investiga tor discretion provided the reduction is 
symmetrical and results in no more than -0.50 D SE residual (i.e., 
uncorrected) myopia. Prescribing a correction that yields more 
than 0.50 D more minus SE than the cycloplegic refraction SE is 
considered deliberate  overminus and is not allowed . 
• Note that the refractive correction guidelines and the requirement 
to wear refractive correction for at least 2 week s apply not only to 
participants who require refractive correction under the above 
criteria but also to any o ther participant who is wearing refractive 
correction.  
9. Gestational age > 30 weeks  
10. Birth weight > 1500 grams  
11. Patient and/or parent understands protocol, is willing to enroll, and is 
willing to accept that other (i.e., nonrandomized) treatment for IXT 
will not be offered by [CONTACT_11202] 3 months  
12. Parent has phone and is willing to be contact[CONTACT_352710]  
13. Relocation outside of area of an active PEDIG site within 3 months  
 
IXT7P ROTV1.0_19A PR2022 PAGE 11 OF 50 PARTICIPANT AREA  DESCRIPTION  
not anticipated  
 
Exclusion Criteria:  
Individuals meeting any of the following criteria at baseline will be 
excluded from study participation : 
1. Prior strabismus, intraocular, or refractive surgery (including 
BOTOX injection)  
2. Prior nonsurgical treatment for IXT  (e.g., patching, vergence therapy, 
vision therapy/orthoptics,  base-in prism, or deliberate overminus 
(more than 1.00 D) spectacles of >1week duration  within the past 
year 
3. Previous amblyopia treatment other than refractive correction  
4. Diplopia more than 2 times per day by [CONTACT_352711]  
5. Paretic or restrictive strabismus  
6. Craniofacial malformations affecting the orbits  
7. Ocular disorders which would reduce VA (except refractive error)  
8. Severe developmental delay that would interfere with treatment or 
evaluation (in the opi[INVESTIGATOR_871]).  Participants with mild 
speech delay or reading and/or learning disabilities or ADHD are not 
excluded.  
9. Neurological anomaly that could affect ocular motility (e.g., cerebral 
palsy, Down syndrome)  
10. Immediate  family member (child or sibling) of any investigative site 
personnel directly affiliated with this study.  
11. Known allergy to adhesive patches.  
12. Known allergy to silicone.  
Sample Size  72 (36 observation , 36 full-time patching)  
Phase  Phase 3  
Treatment Groups  Random assignment to:  
• Observation   
• Full-time patching (all waking hours, 7 days/week)  
Participant Duration  3 months after randomization   
Protocol Overview/Synopsis  Participants will be randomly assigned to observation or full -time 
patching. All parents will receive a phone call at 4 weeks to answer any 
questions about observation or patching treatment. Participants will be 
followed for 3 months .  
 
 
IXT7P ROTV1.0_19A PR2022 PAGE 12 OF 50 STUDY SUMMARY FLOW  CHART  
 
Enrollment/Baseline Visit  
•Informed consent  
•Pediatric Eye Questionnaire (PedEyeQ)  
•IXT S ymptom  Survey  
•Diplopia Assessment by [CONTACT_85189]  
•Randot Preschool Stereoacuity  (40 cm)  
•Exotropia c ontrol #1 (distance and near)  
•Divergence and convergence fusional amplitudes  
•Exotropia c ontrol #2 (distance and near)  
•Ocular alignment (cover/uncover , SPCT, PACT)  
•Exotropia c ontrol #3 (distance and near)  
•Suppression  
•Retinal correspondence  (ages 6 -8 years)  
•Assessment of eligibility  
  
Randomize  
Major Eligibility Criteria  
•Children aged 3 to < 9 years  
•Intermittent exotropia meeting all the following criteria:  
•Intermittent or constant XT at distance (mean distance control 2.[ADDRESS_439005] 1 measure of 3, 4 or 5  
•IXT or exophoria or orthophoria at near ( cannot have control score of 5 on all 3 near assessments)  
•Distance deviation between 1 5∆ and 50∆ by [CONTACT_225827]  
•Near deviation between 0∆ and 50∆ by [CONTACT_225827]  
•Near deviation does not exceed distance by [CONTACT_726] 10∆ by [CONTACT_225827]  
•No prior strabismus, intraocular, or refractive surgery (including BOTOX injection)  
•No previous nonsurgical treatment of >[ADDRESS_439006] year  
•No amblyopia treatment other than refractive correction  
•No diplopia more than 2 times per day by [CONTACT_146909]  
•Refractive error between -6.00 D SE and +2.00 D SE (inclusive) based on a cycloplegic refraction within 7 months  
•Age-normal VA (3 yrs = 20/50 or better; 4 yrs = 20/40 or better; 5 -6 yrs = 20/32 or be tter; 7 -8 yrs = 20/25 or better)  
•No interocular VA difference more than 0.2 logMAR  
•Wearing appropriate refractive correction for at least 2 weeks 
•No abnormality of the cornea, lens , or central retina   
•No known allergy to adhesive patches or silicone.  
3 months (±2 weeks) Primary Outcome  
•Patch a dherence monitoring  (patching group only)  
•Pediatric Eye Questionnaire (PedEyeQ)  
•IXT S ymptom  Survey  
•Diplopia Assessment by [CONTACT_85189]  
•Randot Preschool Stereoacuity (40 cm)  (masked)  
•Exotropia c ontrol #1 (distance and near) (masked)  
•Divergence and c onvergence fusional amplitudes (masked)  
•Exotropia c ontrol #2 (distance and near) (masked)  
•Ocular alignment (cover/uncover , SPCT, PACT)  (masked)  
•Exotropia c ontrol #3 (distance and near) (masked)  
•Suppres sion (masked)  
•Retinal correspondence  (ages 6 -8 years)  (masked)  
Observation  
 Patching  All 
waking hours  
4 weeks (± 1 week): Phone Call 
 
IXT7P ROTV1.0_19A PR2022 PAGE 13 OF 50 SCHEDULE OF STUDY VISITS AND PROCEDURES  
a Retinal correspondence to be measured only in children 6, 7, or 8 years of age at randomization  
. Enrollment  4-Week 
Call 3-Month 
Visit  
Consent  X   
Demographics / Medical History  X   
Treatment Compliance   X X 
Quality of Life Survey  X  X 
IXT Symptom Survey  X  X 
Diplopia Assessment by [CONTACT_85189]  X  X 
Distance Visual Acuity  X  X 
Randot Preschool Stereoacuity  X  X 
Exotropia Control (distance and near)  X  X 
Amplitude Testing (Divergence and Convergence)  X  X 
Ocular Alignment (distance and near)  X  X 
Suppression (distance)  X  X 
Retinal Correspondence*  X  X 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 14 OF 50 Chapter 1:  Background Information  1 
1.1 Epi[INVESTIGATOR_352697]  2 
Intermittent exotropia (IXT) is the most common form of childhood -onset exotropia,1,[ADDRESS_439007] been 6 
proposed.8,9 7 
IXT is characterized by  [CONTACT_352712] 8 
without deviation at near fixation. Pseudonyms include periodic exotropia and exotropia of 9 
inattention. In addition to being present for distan ce viewing, exotropia  may also occur at near 10 
and with inattention, in bright sunlight , or when tired. Closure of one eye in bright sunlight  and 11 
sensitivity to sunlight10-12 are also characteristic features.  Normal binocular single vision is 12 
typi[INVESTIGATOR_352698], with normal (occasionally subnormal) 13 
stereoacuity.13,14 Diplopia is rarely reported.15 14 
IXT is characterized by [CONTACT_352713] :[ADDRESS_439008], but normal binocular single vision with normal stereoacuity is 16 
reestablished when the deviation is controlled (albeit with persistent temporal r etinal suppression 17 
in some children17). In addition, some children with IXT are thought to covary between normal 18 
and anomalous  retinal correspondence  (ARC)16,[ADDRESS_439009] udies evaluating treatments for IXT , there are relatively few 25 
data on treatment effectiveness14 and current practice patterns are fragmented.20,21  26 
In addition, long -term success following treatment appears elus ive, and specific reasons for 27 
treatment failure are unclear. Popular explanations include the possibility that persistent sensory 28 
maladaptations (suppression and/or anomalous retinal correspondence), as well as inadequate 29 
fusional amplitudes, may be responsible for recurrence of the exotropia following treatment.  30 
To provide context for the proposed randomized clinical trial (RCT), the following summary 31 
briefly describes commonly used management strategies along with data from previous RCTs.  32 
1.2.1 Observati on 33 
We are aware of two previous RCTs in which subjects with IXT were randomized to 34 
observation. The PEDIG IXT2 studies22,23 randomized children to observation versus part -time 35 
patching. In the older cohort randomized to observation (3 to < 10 years at enrollment), 36 
deterioration of IXT (constant exotropia ≥10Δ at distance and near or ≥[ADDRESS_439010] previous measure, or being prescribed treatment despi[INVESTIGATOR_352699] 38 
met motor or stereo deterioration) was met in 25 of 183 by 3 years (15%, 95% confidence 39 
interval = 10% -22%), 12 of whom were prescribed treatment without meeting motor or 40 
stereoacuity criteria.24 However, of the  132 who completed the 3 -year visit and had not been 41 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 15 OF 50 treated during the study, only 1 (<1%) met motor or stereoacuity deterioration criteria at 3 42 
years.24 Of those olde r children randomized to observation who remained untreated over the 3 43 
years, “complete or near complete resolution” (exodeviation <10 Δ at distance and near, no 44 
reduction in stereoacuity, and no other nonsurgical treatment for IXT, having never met 45 
deterioration criteria) was met in 6 (7%) of 86.25  46 
In the younger cohort randomized to observation (12 -35 months at enrollment), deterioration of 47 
IXT (constant exotropia ≥10 prism diopters at distance and near or treatment prescribed despi[INVESTIGATOR_040] 48 
not having  met motor deterioration) occurred in 28% (95% CI = 20% –39%) by 3 years.26 Of the 49 
24 participants meeting the primary outcome of deterioratio n, seven met motor deterioration and 50 
17 were prescribed treatment without meeting motor deterioration.26 The cumulative probability 51 
of motor deterioration by 3 years was 10% (95% CI = 5% –19%).  [ADDRESS_439011] of surgery versus observation for IXT, Clarke et al27 found 2 (9%) of 22 in the 53 
observation group showed si gnificant improvement in control (improved 3 and 4 points  on the 54 
office control scale) after 9 months of follow -up. 55 
1.2.2 Surgery  56 
The aim of surgery for IXT is to reduce the magnitude of the exodeviation (or eliminate it 57 
completely) such that any residual deviation can be easily compensated by [CONTACT_352714] [ADDRESS_439012] evaluated surgery for IXT.14 PEDIG 59 
(IXT1)28 compared bilateral and unilateral surgery and found complete or near -complete 60 
resolution of IXT  in 30% of participants overall at 3 years postoperatively  (complete or near 61 
complete resolution defined as exodeviation <[ADDRESS_439013] ance and near, reduction of ≥[ADDRESS_439014], esotropia <[ADDRESS_439015] at distance and near, no ≥[ADDRESS_439016] reduction in stereoacuity, no 63 
reoperation, no nonsurgical treatment for recurrent or residual exodeviation, and having never 64 
met failure criteria [exotropia  ≥10Δ by [CONTACT_352715], constant esotropia  ≥6Δ by [ADDRESS_439017] at distance or near, and ≥[ADDRESS_439018] reduction in stereoacuity ]). In a separate RCT , 66 
Kushner29 also compared unilateral versus bilateral surgery and found a satisfactory outcome 67 
(aligned within  10Δ of exophoria and 5Δ of esophoria) in 82% and 52% respectively, but 68 
outcomes were evaluated at only one year postoperatively. In IXT1,30 younger age (3 to <5 69 
years) was associated with a lower risk of failure by 3 years (28% vs 50%) ; however, reasons for 70 
failure versus success were not explored in Kushner’s RCT.  71 
1.2.3 Nonsurgical treatments  72 
The aim of nonsurgical treatment for IXT is to improve the strength and/or quality of binocular 73 
single vision (reducing suppression, increasing fusional am plitudes), thereby [CONTACT_352716] 74 
of the exodeviation. Commonly utilized non -surgical management strategies include, vision 75 
therapy, overminus lenses , relieving or correcting base -in prism , and part -time patching.  76 
Vision therapy:  [ADDRESS_439019] is planned and due 78 
to commence in 2021 ([STUDY_ID_REMOVED] ).  79 
Overminus optical correction:  [ADDRESS_439020] ( IXT5; [STUDY_ID_REMOVED])  conducted by [CONTACT_225813],31 randomized 3 - to 10 - 81 
years old with IXT to overminus spectacle s (−2.50 D over cycloplegic refraction for 12 months) 82 
vs non -overminus spectacles  and found better mean distance control at 12 months (in correction)  83 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 16 OF 50 for p articipants treated with overminus spectacles (n=196) than those  with non-overminus 84 
spectacles (n=190) (1.8 vs 2.8 points ; adjusted difference, −0.8; 95% CI, −1.0 to −0.5; P< 0.001). 85 
Factors associated with better versus worse control  at outcome were not evaluated.  However , a 86 
greater myopic shift occurred in those with overminus  vs non -overminus treatment  (−0.42 D vs 87 
−0.04 D; adjusted difference, −0.37 D; 95% CI, −0.49 to −0.26 D; P<0.001) , resulting in the 88 
overminus spectacles being discontinued before follow -up was complete in some participants.31  89 
Prism correction:  [ADDRESS_439021] conducted by [CONTACT_225813] 91 
(IXT6; [STUDY_ID_REMOVED] ). The primary outcome  was change in exodeviation control score, but 92 
factors associated with success versus failure of treatment were not evaluated . Results are due to 93 
be published later this year.  94 
Patching:  [ADDRESS_439022] frequently prescribed nonsurgical treatments for IXT and is described 96 
in detail below (section 1.3).  97 
 98 
1.3 Patching  99 
1.3.1 Current clinical practice  100 
Prevailing clinical practice is to prescribe a low dose of 2 -4 hours/day, and to either patch 101 
alternate eyes, alternate days, or patch the eye preferred for fixation (if present). Some clinicians 102 
prescribe for longer periods of time such as 6 -8 hours/day o r full -time (all waking hours) based [ADDRESS_439023] s 111 
long-term.  112 
1.3.2 Previous Randomized Trials of Patching Treatment  113 
Akbari et al 202 034: Akbari et al  recent ly published  a RCT34 compar ing part-time patching (2 114 
hours a day , alternating eyes ) to observation in 76 children who were 3- to 8-years-old with IXT . 115 
The primary outcome was a single measure of control , using a modification of the Office Control 116 
Score35 at 3 and 6 months  (on treatment). Control s cores ranged from 0 (phoria) to 6 (constant 117 
exotropia) and were better (lower score) in the patching group at 3 months (distance: 2.3±1 .0 118 
points  vs 2.7±1.1  points ; P=0.03 ; near: 1.2±0.7  points  vs 1.5±0.6  points ; P=0.003) , and at 6 119 
months  (distance: 2.4±1.1 points  vs 2.8±1.2  points ; P=0.03; near:  1.0±0.6 points  vs 1.6±0.9  120 
points ; P=0.003).  Nevertheless, post -treatment outcomes, as well as effects on suppression, angle [ADDRESS_439024] that many participants had persistent intermittent exotropia.  123 
PEDIG 201422 and PEDIG 201523: Two PEDIG RCTs evaluated part -time patching (3 hours a 124 
day for 5 months) versus observation in 12- to 35-month -olds23 and 3 - to <11 -year-olds22 with 125 
IXT.  In published secondary analyses of 6 -month outcomes ([ADDRESS_439025] cessation of patching 126 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 17 OF 50 treatment), mean control scores and mean angle of deviation were compared between patching 127 
and observation groups. For 12 - to 35 -month -olds, mean distance control score s were better 128 
(lower) in the patching group compared with the observation group (2.3 points  vs 2.8 points ; 129 
P=0.02) (near control scores were similar: 1.1 points  vs 1.4 points ; P=0.26).23 In addition, mean 130 
distance angle of deviation (PACT) was significantly smaller in the patched group (24.9Δ vs 131 
27.9Δ, P=0.02 )(near angle was similar:  17.0Δ vs 19.3Δ, P=0.10). For 3- to <11 -year-olds, 132 
dista nce control scores were similar between groups (2.0 points  patching vs 2.3 points  133 
observation; P=0.094) but near control scores were lower in the patching group (0.9 points  vs 1.2 134 
points ; P=0.013) .[ADDRESS_439026] was 22.2Δ in the patching group vs 23.8Δ 135 
in the observation group (P=0.012) at distance and 15.4Δ vs 17.6Δ ( P=0.11) at near.  [ADDRESS_439027] hoc analyses 137 
(publication in process)  of 3- to <11-year-olds with a control score of 2 or more at enrollment 138 
and a 3 -month on -treatment examination (matching current study inclusion criteria and primary 139 
outcome time -point) distance control improved 0. 4 points  in the observation group (n= 147) and 140 
0.8 point s in the patching group (n=1 25) (mean difference 0.41 points  (95% CI, 0.12 to 0.70 141 
points ). Angle of deviation improved 0. 2Δ in the observation group and 2. 3Δ in the patching 142 
group  (mean difference 2.1Δ (0.6 to 3.6Δ) . 143 
Nevertheless, in both the 12 - to 35 -month and 3 - to <[ADDRESS_439028] evaluated patching for IXT.16,36,37 While there 148 
are intrinsic challenges when interpreting data from non -randomized studies, the following are 149 
selected for more detailed review either because they provi de additional information on potential 150 
effects of full -time patching, and/or provide some insight regarding how patching may impact 151 
sensory adaptations, the angle of deviation , or fusional amplitudes.  152 
Full-time Patching  153 
Iacobucci  & Henderson 196533: Twenty -eight children with IXT, scheduled for surgery, were 154 
selected (“at random”) for full -time patching for [ADDRESS_439029] reduced by a mean of 5.8 ±1.1Δ from baseline to 3 157 
months in the patching group, compared with an increase of 1.8 ±0.4Δ in the control group. Near [ADDRESS_439030] reduced by a mean of 4.6 ±1Δ from baseline to 3 months in the 159 
patching group, compared with an increase of 1.3 ±0.5Δ in the control group. Eleven of 28 160 
patched patients and 20 of 38 control patients we re constant exotropia at distance at baseline; of 161 
these, 8 (73%) of 11 in the patching group and 0 of 20 in the control group became intermittent 162 
or phoric at 3 months.  163 
Flynn et al 197 632: In a prospective study, Flynn and colleagues prescribed full -time patching for 164 
4-12 weeks to 31 children (mean age 7.6 years, range 3 to 13 years) with IXT. Mean angle of 165 
deviation pre -treatment was 20 ±7Δ at distance and 15±12Δ at near. Nine of 31 had undergone 166 
previous surgery. Following patching treatment, 7 (23%) of 31 showed dramatic improvement 167 
such that “t he deviation became almost completely phoric , fusion improved , and all evidence of 168 
suppression on the synoptophore or in free space disappeared. ” Fourteen  of 31 patients had a  169 
reduction in angle of deviation and a change from tropia to intermittent tropia or phoria . In 12 of 170 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 18 OF 50 31 patients there was a measurable improvement in suppression with disappearance of the 171 
suppression scotoma. Increase in the range of fusional amplitudes occurred in 9 of these 12 172 
patients.  Of note, Flynn et al32 report that some patients did not respond positively to patching, 173 
with 12 showing an increase in angle of deviation (mean 5Δ, ran ge 2Δ to 15Δ) and [ADDRESS_439031]  176 
Patching is considered “anti -suppression” therapy, affecting exodeviation control by [CONTACT_352717] [ADDRESS_439032], although patching is designated “anti - 183 
suppression” treatmen t, there are few data demonstrating that changes in suppression occur with [ADDRESS_439033] used occlusion dose monitors (ODMs) to record actual [ADDRESS_439034]  209 
relationship.   210 
Recently, a new method of monitoring patching adherence has become available and is being 211 
used in a concurrent PEDIG amblyopia study (ATS22 , [STUDY_ID_REMOVED] ). TheraMon®, a 212 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 19 OF 50 thermosensor device, appears to work well for monitoring adherence with amblyopia patching 213 
treatments in children.51 We propose utilizing the TheraMon® in the current study to enable 214 
important secondary analyses of outcome in relation to actual (rather than prescribed) wear time.  [ADDRESS_439035] of patching on control of IXT, and even on angle of 218 
deviation, there remain many unanswered questions regarding treatment effectiveness. Such 219 
questions include:  220 
- Is prescribed full -time patching more effective for improving control and/or reducing 221 
angle of deviation than observation alone?  222 
- Does patching alter suppression, angle of deviation, fusional amplitudes , or 223 
anomalous  retinal correspondence, and are such changes related to exodeviation 224 
control?  225 
- Is there a dos e-response relationship (greater improvement with more actual patching 226 
time)?  227 
- Which clinical and demographic characteristics , if any,  are associated with 228 
improvement in exodeviation control and/or treatment success?   229 
1.7 Rationale for Present Study  230 
IXT is a c ommon eye condition , but long-term surgical treatment outcomes are disappointing , 231 
with high failure rates due to recurrence or undercorrection of the exodeviation. Patching is a 232 
commonly used nonsurgical treatment for which there is some evidence of short -term treatment 233 
benefit (improved exodeviation control and reduced angle of deviation) when prescribed 2 -3 234 
hours/day. Nevertheless, the extent to which patching is effective if worn for long periods of [ADDRESS_439036] is maintained off -treatment, and how full -time 241 
patching compares to other treatment strategies.  242 
In addition, t his study would provide evidence of the ability of patching to  alter suppression, 243 
anomalous  retinal correspondence, and fusional amplitudes, and the  relationships of these 244 
clinical characteristics with treatment success, failure, and improvement of IXT. This study 245 
provides an opportunity to explore such relationships , and data are expected to create hypotheses 246 
for future studies.   247 
1.8 Study Objectives  248 
Determine whether full -time patching  is more effective than observation for improving distance 249 
control of IXT after 3 months of treatment (on -treatment outcome) . 250 
 251 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 20 OF 50 1.9 Potential Risks and Benefits of Study Treatment   252 
1.9.1 Known Potential Risks  253 
There is a risk that patching may create diplopia that then becomes troublesome to the patient, 254 
but this complication  is seldom reported. It is possible that some patients will show wor sening of 255 
IXT control or increase in magnitude with patching32 or observation ,22 but deterioration criteria 256 
will be assessed a fter 3 months and the short 3 -month duration allow s for cessation of patch ing 257 
treatment and/or commencement of other treatment should  deterioration  of the IXT  occur. Skin 258 
irritation may occur . If persistent skin irritation occurs due to the adhesive patch, the participant 259 
will be provided with a fabric patch to wear on their glasses (plano glasses will be provided for 260 
children who are not already wearing glasses). Patching could potentially cause a decrease of VA [ADDRESS_439037] always reversible. One potential risk with observing IXT without 263 
treatment is that suppression may increase in density over time. An increase in the density of 264 
supp ression may predispose the child to worse  motor and sensory outcomes in the  long term, but 265 
with a 3 -month study duration there is unlikely to be a significant change, and furthermore this 266 
has not been previously studied  to know if and when this occurs.  267 
1.9.2 Known Potential Benefits   268 
The potential benefits of patching are improved exodeviation control , reduced angle of deviation, 269 
reduced suppression, and/or increased fusional amplitudes.  [ADDRESS_439038], approximately 7% of [ADDRESS_439039] benefit of 273 
observation.  274 
1.10 Risks of Examination or Testing Procedures  275 
The procedures in this study are part of daily eye care practice in the [LOCATION_002] and pose no 276 
known risks. As part of a routine usual -care exam, the participant may receive 277 
cycloplegic/dilating eye drops.  278 
 279 
1.11 Risk Assessment  280 
There are no risks involved in this study that would not be part of usual care  when treating with 281 
either patching or by [CONTACT_211463] . The protocol’s level of risk is consistent with [ADDRESS_439040] their origin in the Declaration of 288 
Helsinki, with the protocol described herein, and with the standards of Good Clinical Practice 289 
(GCP).  290 
 
IXT7P ROTV1.0_19A PR2022 PAGE 21 OF 50 Chapter 2:  Study Enrollment and Randomization  [ADDRESS_439041] the 301 
overall recruitment goal.  The overall number of participants with an i nterocular diffe rence in 302 
distance VA of 2 logMAR lines (10 letters  on E-ETDRS for patients  ≥7 years old)  will be 303 
limited to 14.  304 
 305 
 Informed Consent  306 
Children with IXT who are 3 to <9 years of age attending ophthalmology or optometry 307 
outpatient visits will be identified.  308 
 309 
Families who qualify for the study will be approached by [CONTACT_352718]. The 310 
study will be discussed with the child’s parent(s) or guardian(s) [referred to subse quently as 311 
parent(s)]. Parent(s) who express an interest in the study will be given a copy of the informed [ADDRESS_439042] be obtained from a parent and written or 313 
verbal assent from the child (depending on age and local  IRB requirements) prior to performing 314 
any study -specific procedures that are not part of the child’s routine care.  315 
 316 
A child is considered enrolled into the study when the informed consent form has been signed by 317 
the parent, the assent form has been signed  by [CONTACT_2252] (when applicable), and the investigator [ADDRESS_439043] -of-care outpatient visit or from a referral from another provider, will 324 
be eligible for the study if they meet all the following criteria:  325 
1. Age 3 to < 9 years  326 
2. IXT meeting all the following criteria:  327 
• Intermittent or constant XT at distance (mean distance contro l 2.0 or more) with at [ADDRESS_439044] 1 measure of 3, 4 or 5  (i.e., indicating spontaneous tropia)  on control testing  329 
• Either IXT, exophoria , or orthophoria  at near ( cannot have control score of 5 on all 3 330 
near assessments)  331 
• Distance exodeviation between 15∆ and 50∆ by [CONTACT_225827]  332 
• Near exodeviation between 0∆ and 50∆ by [CONTACT_225827]  333 
• Near exodeviation does not exceed distance by [CONTACT_726] 10∆ by [CONTACT_225827]  334 
3. Age-normal visual acuity in both eyes:56-58 335 
 
IXT7P ROTV1.0_19A PR2022 PAGE 22 OF 50 • 3 years: 20/50 or better (>=63 letters)  336 
• 4 years: 20/40 or better (>=68 letters)  337 
• 5-6 years: 20/32 or better (>=73 letters)  338 
• 7-<9 years: 20/25 or better  (>=78 letters)  339 
4. Interocular difference in distance VA of 2 logMAR lines or less (10 letters or less on E- 340 
ETDRS for patients  ≥7 years old) . Testing by [CONTACT_352709]  3 to < 7 years 341 
old and by E -ETDRS for participants  ≥7 years old.  342 
o The overall number of participants with an i nterocular difference in distance VA 343 
of 2 logMAR lines (10 letters on E -ETDRS for patients ≥7 years old) will be 344 
limited to 1 4. 345 
5. Refractive error b etween -6.00 D SE and +2.00 D SE (inclusive)  based on cycloplegic [ADDRESS_439045] 2 349 
week s: 350 
• Myopia > -0.50 D spherical equivalent (SE)  in either eye  351 
• Anisometropia > 1.00 D SE 352 
• Astigmatism in either eye > 1.00 D  353 
7. Any r efractive correction worn at enrollment (required or not) must meet the following 354 
guidelines  based on cycloplegic refraction performed within the prior 7 months : 355 
• Anisometropia SE must be within 0. 50 D of the full anisometropic difference 356 
correction  357 
• Astigmatism must be corrected within 0.50 D   358 
• Axis must be within ±10 degrees if cylinder power is ≤1.00 D and within ±5 359 
degrees if cylinder power is >1.00 D.  360 
• For hyperopia, the spherical component can be reduced at investigator discretion 361 
provided the redu ction is symmetrical  and does not meet the definition of 362 
deliberate overminus (see below) .  363 
• For refractive errors with an emmetropic or myopic SE , the intent is to fully [ADDRESS_439046], but the spherical component can be undercorrected at investigator 365 
discretion provided the reduction is symmetrical and results in no more than  366 
-0.50 D SE residual (i.e., uncorrected) myopia. Deliberate overminus is not 367 
allowed . 368 
• Deliberate overminus is defined for this protocol as a ny refractive correction 369 
prescribed to yield lenses that are overminused by [CONTACT_726] -0.50D SE than 370 
cycloplegic refraction SE.  371 
▪ Less than the full cycloplegic hyperopic correction (i.e., prescri bing 372 
reduced plus)  or no correction for a hyperopic SE refractive error  is 373 
not considered the same as overminusing for this protocol (because [ADDRESS_439047] patients without IXT but with hyperopic SE refractions up to 375 
+2.00 D SE  would not typi[INVESTIGATOR_352696] a refractive correction. ) 376 
• Note that the refractive correction guidelines and the requirement to wear [ADDRESS_439048] 2 week s apply not only to pa rticipants  who 378 
require refractive correction under the ab ove criteria but also to any other 379 
participant  who is wearing refractive correction.  380 
8. Gestational age > 3 0 weeks  381 
 
IXT7P ROTV1.0_19A PR2022 PAGE 23 OF 50 9. Birth weight > 1500 grams  382 
10. Patient and/or parent understands protocol, is willing to enroll,  and is willing to accept 383 
that other treatment  for IXT will not be offered for 3 months  384 
11. Parent has phone and is willing to be contact[CONTACT_352719] 385 
12. Relocation outside of area of an active PEDIG site within next 3 months  not anticipated  386 
 387 
 Exclusion Criteria  388 
Individuals meeting any of the following criteria at baseline will be excluded from study 389 
participation.  390 
1. Prior strabismus, intraocular, or refractive surgery (including BOTOX injection)  391 
2. Prior nonsurgical treatment for IXT  (e.g., patching, vergence therapy, vision 392 
therapy/orthoptics,  base-in prism,  or deliberate overminus with spectacles more than 393 
1.00 D) for >[ADDRESS_439049] 1 year  394 
3. Previous amblyopia treatment other than refractive correction  395 
4. Diplopia more than 2 times per day by [CONTACT_352720] t 396 
5. Paretic or restrictive strabismus  397 
6. Craniofacial malformations affecting the orbits  398 
7. Ocular disorders which would reduce VA (except refractive error)  399 
8. Severe  developmental delay that would interfere with treatment or evaluation (in the 400 
opi[INVESTIGATOR_871]).  Participants  with mild speech delay or reading and/or [ADDRESS_439050] ocular  motility (e.g., cerebral palsy, Down 403 
syndrome)  404 
10. Immediate family member (child or sibling) of any investigative site personnel directly 405 
affiliated with this study . 406 
11. Known allergy to adhesive patches.  407 
12. Known allergy to silicone.  408 
 409 
2.3 Historical  Information  410 
Historical information elicited will include the following: date of birth, sex, race, ethnicity, 411 
spectacle correction, and prior treatment  for IXT and amblyopia.   412 
 413 
2.4 Screening and Baseline Procedures   414 
Testing will be done in the order specified below on a single day following  enrollment in the 415 
child’s current refractive correction if worn (any spectacle correction worn must meet the criteria 416 
specified in section 2.2 ) and  without cycloplegia:  417 
1. Eye-Related  Quality of life : Pediatric Eye Questionnaire (PedEyeQ)  418 
• Child questionnaire: Completed by [CONTACT_7683] 5 years and older  419 
• Parent questionnaire: Completed by [CONTACT_352721] 420 
(includes parent and proxy questions)  421 
2. Symptom Survey :  422 
• Intermittent Exotropia Symptom Survey c ompleted by [CONTACT_7683] 5 years or older.  423 
• Single diplopia question to be completed by [CONTACT_7683] 3 or 4 years.  424 
 
IXT7P ROTV1.0_19A PR2022 PAGE 24 OF 50 3. Diplopia Assessment  by [CONTACT_85189] : Assess diplopia presence and frequency over the last week, 425 
by [CONTACT_146909]. If present, classify diplopia frequency as “2 times or less per day” or 426 
“more than 2 times per day.”  427 
4. Monocular Distance VA Testing : Distance VA testing will be performed by a certified 428 
examiner on a certified VA system (EVA or M& S), using the ATS single surround HOTV 429 
for participants 3 to <7 years old and using the E -ETDRS for participants ≥ 7 years. The 430 
same VA testing method used at enrollment will be used again at 3 months .  431 
5. Stereoacuity Testing:  Assessed using the Randot Presc hool Stereotest at near (performed at 432 
40 cm) as  outlined the IXT7 Procedures Manual   433 
6. Control of the Exodeviation #1 : Control of the exodeviation at distance (6 meters) then near 434 
(1/3 meter) will be assessed  using the standardized IXT control scale ,35 as outlined  in the 435 
IXT7 Procedures  Manual.  436 
• Testing must be performed by a pediatric ophthalmologist, pediatric optometrist, or [ADDRESS_439051].  438 
• The same examiner must  assess control for all three assessments of control at each 439 
visit.  440 
8. Divergence  Amplitude Testing : Measured at distance (6 meters) using the PEDIG -approved 441 
prism bar as described in the IXT7 Procedures Manual  442 
• Testing must be performed by a pediatric ophtha lmologist, pediatric optometrist, or [ADDRESS_439052].  444 
• Record the break and recovery points.  445 
9. Convergence Amplitude Testing:  Measured at distance (6 meters) using the PEDIG -approved 446 
prism bar as described in the IXT7 Procedures Manual  447 
• Testing must be performed by a pediatric ophthalmologist, pediatric optometrist, or [ADDRESS_439053].  449 
10. Control of the Exodeviation #2  (repeat) (see item #7). 450 
11. Ocular Alignment  Testing :  451 
• Testing must be performed by a pediatric ophthalmologist, pediatric optometrist, or [ADDRESS_439054].  453 
• Ocular alignment will be assessed by [CONTACT_352722]/uncover test, simultaneous prism and [ADDRESS_439055] (SPCT), and prism and alternate cover test (PACT) in primary gaze at 455 
distance (3 meters) and near (1/3 meter)  as described in the IXT7 Procedures Manual .  456 
12. Contro l of the Exodeviation #3  (repeat) (see item # 7) 457 
13. Suppression : Assessment of suppression at distance  (6 meters)  using the Office Suppression 458 
Test59 as described in the IXT7 Procedures Manual  459 
• Testing must be performed by a pediatric ophthalmologist, pediatric optometrist, or [ADDRESS_439056].  461 
14. Retinal Correspondence  (children 6 to <9 years only) : Assessment of retinal correspondence 462 
will be made when aligned and also when tropic using the Hering -Bielschowsky After Image 463 
Test60 as described in the IXT7 Procedures Manual  using the PEDIG -supplied flash unit.  464 
• Testing must be performed by a pediatric ophthalmologist, pediatric optometrist, or [ADDRESS_439057] .  466 
 467 
 
IXT7P ROTV1.0_19A PR2022 PAGE 25 OF 50 2.5 Randomizati on 468 
Eligible participants will be randomly assigned on the study website to the following  treatment : 469 
 470 
1. Observation for 3 months – no treatment other than refractive correction  471 
2. Full-time patching  (all waking hours) for 3 months (right eye on even days, left eye on odd 472 
days) , in addition to refractive correction   [ADDRESS_439058]  stratified by [CONTACT_352723] 475 
score  at enrollment (2 to <3, 3 to <4, 4 to 5) . A participant is officially randomized when the 476 
website randomization process is completed.   477 
 Observation Group  478 
Participants randomized to observation alone will not be allowed to receive any other  treatment 479 
for IXT, except refractive correction, for 3 months .  480 
 Full-Time Patching Group  481 
Participants randomized to the full-time patching group will patch full -time (all waking hours) 482 
for 3 months  up until the day before the 3 -month primary outcome visit . Daily  alternate patching 483 
will be prescribed  (right eye on even days, left eye on odd day s). No other treatment for IXT will 484 
be used, except for refractive correction.  485 
2.6 Monitoring of Adherence  486 
Site staff will a ctivate and distribute occlusion dose monitors ( ODMs ) for participants 487 
randomized to patching ( patching adherence is not applicable to the observation group).  488 
• Adherence with patching will be monitored throughout the study by [CONTACT_352724] 489 
inside of the patch for participants randomized to patching.   490 
• In addition, parents will be asked to record patch ing wear time and which eye was 491 
patched on a study calendar. 492 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 26 OF 50 Chapter 3:  Study Follow -up 493 
3.1 Study Visits  494 
Study follow up for p articipants randomized in the study is (timed from randomization):  495 
 496 
• 4-week phone call: 4 weeks ± 1 week  497 
• 3-month  (on treatment) primary outcome visit : 3 months ± 2 weeks  498 
• Parents will be instructed to not patch on the day of the visit  499 
 500 
3.2 Phone Call at 4-weeks 501 
Study personnel will call the parent of each participant 4 weeks ± [ADDRESS_439059] any questions or 507 
concerns about the study.  508 
3.3 Masking Procedures  509 
Participants will not be masked to their treatment group, given that they will be asked to patch all 510 
waking hours/day  (full-time patching group) or not at all (observation group). The investigator 511 
treating each participant also will not be masked to treatment group. An examiner masked to 512 
treatmen t group will perform all clinical testing (with the exception of VA  testing and 513 
administration of questionnaires, which may be performed by [CONTACT_352725], certified personnel ) at [ADDRESS_439060]  who is not aware of the participant’s assigned treatment. Because the enrolling 518 
investigator  will be unmasked to treatment group, they will not be allowed to serve as their own 519 
masked examiner.  520 
3.4 Testing Procedures at 3-Month Outcome Visit  521 
The following procedures will be performed  in the order specified below at the 3 -month outcome 522 
visit with the participant wearing their current refractive correction (if worn) , and without 523 
cycloplegia . If unable to complete the entire masked exam  during the office visit , the participant 524 
can return with 10 days to complete all masked testing  (# 6-14 below). Testing procedures #1 -5 525 
below do not need to be repeated if completed at the initial office visit.  526 
 527 
1. Adherence Monitoring  (for patching group):  528 
• Evaluate compliance by [CONTACT_352726]  529 
• Download adherence data from ODM  530 
2. Eye-Related Quality of life : Pediatric Eye Questionnaire (PedEyeQ)  531 
• Child questionnaire: Completed by [CONTACT_7683] 5 years and older  532 
• Parent questionnaire: Completed by [CONTACT_352721] 533 
(includes parent and proxy questions)  534 
3. Symptom Survey :  535 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 27 OF 50 • Intermittent Exotropia S ymptom Survey completed by [CONTACT_7683]  5 years or older . 536 
• Single diplopia question to be completed by [CONTACT_7683] 3 or 4 years.  537 
4. Diplopia Assessment  by [CONTACT_85189] : Assess diplopia presence and frequency over the last week, 538 
by [CONTACT_146909]. If present, classify diplopia frequency as “2 times or less per day” or 539 
“more than 2 times per day.”  540 
5. Monocular Distance VA Testing : Distance VA testing in each eye using the same test 541 
method used at enrollment.  542 
6. Stereoacuity Testing (masked) : Randot Preschool Stereoacuity at 40 cm.   543 
7. Control of the Exodeviation #1 (masked) :  544 
• Distance (6 meters)  545 
• Near (1/3 meter)  546 
• The same examiner must  assess control for all three assessments of control for each visit.  547 
8. Divergence Am plitude Testing (masked) : Measured at distance (6 meters) using a PEDIG - 548 
approved prism bar as described in the IXT7 Procedures Manual  549 
• Record the break and recovery points  550 
9. Convergence Amplitude Testing (masked) : Measured at distance (6 meters) using a PEDIG - 551 
approved prism bar as described in the IXT7 Procedures Manual  552 
• Record the blur, break, and recovery points  553 
10. Control of the Exodeviation #2 (masked)  (repeat)  (see item # 7) 554 
11. Ocular Alignment Testing ( masked ):  555 
• Testing must be performed by a pediatric ophthalmologist, pediatric optometrist, or [ADDRESS_439061].  557 
• Ocular alignment will be assessed by [CONTACT_352722]/uncover test, simultaneous prism and [ADDRESS_439062] (SPCT), and prism and alternate cover test (PACT) in pr imary gaze at 559 
distance (3 meters) and near (1/3 meter) as described in the IXT7 Procedures Manual .   560 
12. Control of the Exodeviation #3 (masked)  (repeat)  (see item # 7) 561 
13. Suppression  (masked) : Assessment at distance using the Office Suppression Test  at distance 562 
(6 meters) as described in  the IXT7 Procedures Manual  563 
14. Retinal correspondence  (masked) : In children aged 6, 7, or [ADDRESS_439063] call one of the Protocol Chairs  to 572 
discuss the case and obtain approval for an early 3 -month outcome visit (if not already in 573 
window) prior to initiating any non -randomized treatment for IXT.  [ADDRESS_439064] or damaged after randomization but before the 3-month 578 
outcome visit, the spectacles may only be replaced with the same spectacle prescription that was 579 
prescribed at randomization.   580 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 29 OF 50 Chapter 4:  Testing Procedures and Que stionnaires  [ADDRESS_439065] procedures will be completed for all three treatment groups at each visit as 583 
defined in the IXT Procedures Manual:  584 
1. Monocular VA Testing : Distance VA will be tested in both eyes with the participant wearing [ADDRESS_439066] be perfo rmed 587 
by a certified examiner on a certified VA system (EVA or M&S), using the ATS single 588 
surround HOTV for participants 3 to <7 years old and using the E -ETDRS for participants ≥ [ADDRESS_439067] : The Randot Preschool Stereoacuity Test measures 6 592 
levels (40 to 800 seconds of arc) of stereoacuity at near ( 40 cm). The test consists of [ADDRESS_439068] be administered by a certified examiner. The certified examiner will be 599 
required to be masked to treatment group. Testing time is approximately 2 -4 minutes.  600 
3. Ocular Alignment : Ocular alignment will be assessed by [CONTACT_352722]/uncover test , simultaneous [ADDRESS_439069] when tropia present by [CONTACT_352727]/u ncover test  (SPCT) , and prism and [ADDRESS_439070] (PACT) , using the PEDIG -approved IXT7 prism bar,  in primary gaze at 603 
distance ( 6 meters) and at near (33 cm) as outlined in the IXT7  Procedures Manual . The 604 
examiner will be required to be masked to treatment group. Testing time is approximately 2- 605 
4 minutes.  606 
4. Cycloplegic Refraction : A cycloplegic refraction will be done prior to enrollment and only if 607 
clinically indicated thereafter . After administration of eye drops, it typi[INVESTIGATOR_20187] 30 minutes 608 
to achieve cycloplegia, and testing time for refraction of both eyes is in the range of 2 to 10 609 
minutes.  610 
5. Suppression Testing:  Suppression will be assessed using the Office Suppression Test  which [ADDRESS_439071], or certified orthoptis t. The examiner will be required 614 
to be masked to treatment group.  Testing time is approximately 3 -5 minutes.  615 
6. Retinal Correspondence  Testing : In children 6, 7, or [ADDRESS_439072] overall status as either:  [ADDRESS_439073]  as outlined in the IXT7  Procedures Manual . The examiner will be required to be 621 
masked to treatment group.  Testing time is approximately 3 -5 minutes.  622 
 623 
7. Control of IXT:  Assessment of IXT control will be performed using the Office Control 624 
Scale35 at both distance (6 meters) and near (1/3 meter), fixating  an accommodative target. [ADDRESS_439074] distance separately.  629 
Intermittent Exotropia Control Scale  630 
5 = Constant Exotropia  631 
4 = Exotropia > 50% of the 30 -second period before dissociation  632 
3 = Exotropia < 50% of the 30 -second period before dissociation  633 
2 = No exotropia unless dissociated, recovers in >5 seconds  634 
1 = No exotropia unless dissoci ated, recovers in 1 -5 seconds  635 
0 = No exotropia unless dissociated, recovers in <1 second (phoria)  636 
Not applicable = No exodeviation present  637 
 638 
Directions :  639 
Step1 : Assessment before any dissociation: Eye alignment is observed for a 30 -second period 640 
with distance fixation.  The time in seconds that a spontaneous IXT is observed is 641 
counted, and the appropriate control score (3, 4, or 5) is assigned for distance fixation. 642 
This is then repeated for near fixation for another 30 -second period; if an exotropia is  643 
observed, then the time in seconds that an eye is observed to be exotropic is counted 644 
and the appropriate score of 3, 4, or 5 is assigned.  If a score of ≥3 is present, then Step 645 
2 (dissociation) is not required for that test distance. First distance and t hen near 646 
fixation are assessed before any dissociation (i.e., before step 2).  647 
Step 2 : Assessment with standardized dissociation is performed only if spontaneous 648 
exotropia is NOT observed during step 1 (control was not a 3, 4, or 5).  Instead, control 649 
will b e a 0, 1, or 2; this is determined based on the worst score determined from 3 650 
successive 10 -second periods of dissociation:  651 
• An occluder is placed over the right eye for 10 seconds and then removed; the 652 
length of time it takes for the re -establishment of fu sion is measured in seconds.  653 
• The left eye is then occluded for a 10 -second period (second assessment under 654 
dissociation) and after uncovering the eye, the time for re -establishment of fusion 655 
is similarly measured in seconds.  656 
• A third assessment is performed , by [CONTACT_352728] [ADDRESS_439075] two 10 -second dissociations.  After uncovering the eye, the 658 
length of time (in seconds) it takes for the reestablishment of fusion is measured [ADDRESS_439076] time of the three assessments, if a score of 2 (>5 663 
seconds recovery) is noted on the first or second dissociation, then subsequent 664 
dissociation(s) are not needed.  [ADDRESS_439077], the control scale applies to the exodeviation.  667 
8. Measurement of Divergence Amplitude:  Testing must be performed by a pediatric [ADDRESS_439078].  The examiner will be required 669 
to be masked to treatment group . Testing time is approximately 2-4 minutes.  670 
• Divergence  amplitude to be measured at distance  (6 meters)  671 
• Using the PEDIG -approved IXT [ADDRESS_439079] the break, and recovery points 672 
according to the IXT7 Testing Procedures Manual.  673 
• If manifest exotropia is present at the time of testing, amplitude testing will be 674 
recorded as “ unable .” 675 
 676 
9. Meas urement of Convergence Amplitude s: Testing must be performed by a pediatric [ADDRESS_439080]. The e xaminer will be required 678 
to be masked to treatment group.  Testing time is approximately 2-4 minutes.  679 
• Convergence amplitude to be measured at distance  (6 meters)  680 
• Using the PEDIG -approved IXT [ADDRESS_439081] the blur, break, and recovery 681 
points according to the IXT7 Testing Procedures Manual.  682 
• If manifest exotropia is present at the time of testing, amplitude testing will be 683 
recorded as “ unable .” 684 
 685 
The following information will be collected b y interviewing the parent(s)  or reviewing the [ADDRESS_439082] : 687 
 688 
1) Date of birth, sex, race, ethnicity, spectacle correction, and prior treatment for IXT . 689 
2) Assessment of Adverse Events: All adverse events including ocular adverse events, and 690 
any events judged by [CONTACT_352729], occurring 691 
between the time of initiating study eye treatment and the 12 -month outcome exam will 692 
be recorded.  693 
 694 
Each questionnaire is described briefly below.  The procedures for administration are described in 695 
the IXT7 Testing Procedures Manual . 696 
 697 
1. Pediatric Eye Questionnaire (PedEyeQ)61 698 
The Pediatric Eye Questionnaire (PedEyeQ), is a pediatric eye -related quality of life and 699 
functional vision instrument, validate d for use in children with a variety of pediatric eye 700 
conditions. The PedEyeQ is patient - and parent -derived and consists of age -appropriate Child 701 
and Proxy components as well as a Parent component (to assess the effect on the parent 702 
themselves).   703 
i. The Child PedEyeQ, designed for children 5 to 17 years, has the following 4 704 
domains: Functional Vision, Bothered by [CONTACT_352730]. Social, and Frustration / 705 
Worry.   706 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 32 OF 50 ii. The Proxy PedEyeQ, designed for parents of children 0 to 17 years, has the following 707 
5 domains: Functional Vision, Bothered by [CONTACT_352730], Social, Frustration / [ADDRESS_439083] of the ch ild’s eye condition on the parent 711 
and has the following 4 domains: Impact on Parent and Family, Worry about Child’s 712 
Eye Condition. Worry about Self -perception and Interactions, and Worry about 713 
Functional Vision.   714 
 715 
Each of the Child, Proxy, and Parent domain s is independently scored using established 716 
Rasch look -up tables and converted on a scale of 1 to 100  (each domain scored separately for 717 
each instrument) . Completion time is approximately 10 minutes for the child, 10 -15 minutes 718 
for the parent; child and parent questionnaires can be completed concurrently.  The PedEyeQ 719 
questionnaires administered at enrollment will be the versions repeated throughout the study.   720 
 721 
2. Intermittent Exotropia Symptom Survey62  722 
The Intermittent Exotropia Symptom Survey  is a patient - and parent -derived intermittent 723 
exotropia -related symptom instrument designed to identify the presence and severity of 724 
symptoms in children with IXT. This questionnaire consists of 22 items completed by 725 
children aged 5 years or older.  726 
 727 
• All children will use the three -level response scale (not at all, sometimes, a 728 
lot), administered by [CONTACT_352731] a matching card.   729 
• If possible, children should be positioned such that they are unable to view 730 
their parents during tes ting and parents should be advised not to influence 731 
their child’s responses.  732 
 733 
Children 4 years and younger at enrollment will not complete the full questionnaire , but will 734 
answer the single question (#8) regarding diplopia . Time for completion of the full  Symptom 735 
Survey is 5 -7 minutes.  736 
 737 
3. Assessme nt of Diplopia by [CONTACT_85189]  738 
An estimate of the frequency of diplopia (if any) will be determined by [CONTACT_352732] 739 
whether “your child has complained of double vision over the last week.” If yes, the parent is 740 
asked how frequently the child has complained of double vision: “2 times or less per day,” 741 
“or “more than 2 times per day.” Any study personnel may ask the parent to rate diplopia. 742 
Testing time is approximately 1 minute.  743 
 
IXT7P ROTV1.0_19A PR2022 PAGE 33 OF 50 Chapter 5:  Unanticipated Problem  and Adverse Event Reporting  [ADDRESS_439084] report Unanticipated Probl ems to the IRB within 747 
seven (7) calendar days of recognition. For this protocol, an unanticipated problem is an incident, 748 
experience, or outcome that meets all the following criteria:  749 
• Unexpected (in terms of nature, severity, or frequency) given (a) the re search procedures 750 
that are described in the protocol related documents, such as the IRB -approved research 751 
protocol and informed consent document; and (b) the characteristics of the subject 752 
population being studied  753 
• Related or possibly related to participati on in the research (possibly related means there is [ADDRESS_439085] been caused 755 
by [CONTACT_3459])  756 
• Suggests that the research places participants or others at a greater ri sk of harm than was 757 
previously known or recognized (including physical, psychological, economic, or social 758 
harm)   [ADDRESS_439086] be 762 
reported to the JCHR IRB within seven (7) calendar days of recognition. The Director of the 763 
Human Research Protection Program will report to the appropriate regulatory authorities if the 764 
IRB determines that  the event indeed meets the criteria of an Unanticipated Problem that requires 765 
further reporting.   766 
 767 
5.2 Adverse Events  768 
Although no adverse events are anticipated, any new r eduction in VA  of 3 or more lines ( ≥15 769 
letters  on ETDRS)  or reduction in Randot Preschool Stereoacuity of 2 or more levels , will be 770 
tabulated  between treatment groups.   771 
No surgical procedures are part of the protocol , and no treatments are being prescribed that are 772 
not part of usual care. Investigators will abide by [CONTACT_352733].  773 
5.3 Safety Oversight  774 
A Data and Safety Monitoring Committee (DSMC) will review compi[INVESTIGATOR_352700] [ADDRESS_439087] modifications to 776 
the study protocol or suspension or outright stoppage of the study if deemed necessary based on 777 
the totality of safety data available. Details regarding DSMC review will be documented in a 778 
separate DSMC charter.   779 
The objective of the DSMC review is to decide whether the study (or study treatment for an 780 
individual or study cohort) should continue per protocol, proceed with caution, be further 781 
investigated, be discontinued, or be modified and then proceed . Suspension of enrollment (for a 782 
particular group, a particular study site , or for the entire study) is a potential outcome of a DSMC 783 
safety review.  784 
 785 
 
IXT7P ROTV1.0_19A PR2022 PAGE 34 OF 50 5.4 Stoppi[INVESTIGATOR_2121]  786 
The study may be discontinued by [CONTACT_40972] (with approval of the Data and Safety 787 
Monitoring Committee) prior to the preplanned completion of follow -up for all study 788 
participants . There are no pre -specified  formal guidelines for stoppi[INVESTIGATOR_352701] 789 
efficacy . 790 
 791 
5.5 Partic ipant Discontinuation of Study Treatment  792 
Rules for discontinuing study treatment use are described below.  793 
• The investigator believes it is unsafe for the participant to continue to receive the 794 
treatment.  795 
• The participant or parent requests that the treatme nt be stopped.  796 
Even if the study treatment is discontinued, the participant will be encouraged to remain in the 797 
study through the 3-month visit.  798 
  799 
 
IXT7P ROTV1.0_19A PR2022 PAGE 35 OF 50 Chapter 6:  Miscellaneous Considerations  800 
6.1 Contacts by [CONTACT_352704]  801 
The Jaeb Center serves as the PEDIG Coordinating Center.  The Jaeb Center will be provided 802 
with the parent’s contact [CONTACT_3031].  The Jaeb Center may contact [CONTACT_352734] 803 
participants . Permission for such contacts will be included in the Informed Consent Form.  The 804 
principal purpose of the contacts will be to develop and maintain rapport with the participant  and 805 
family and to help coordinate scheduling of the outcome examinations.   806 
 807 
6.2 Participant Compensation  808 
Participant compensation will be specified in the informed consent form.  809 
6.3 Participant Withdrawal  810 
Participation in the study is voluntary, and a participant may withdraw at any time.  For 811 
participants who withdraw, their data will be used up until the time of withdrawal.  812 
6.4 Confidentiality  813 
For sec urity and confidentiality purposes, participants will be assigned an identifier that will be 814 
used instead of their name.  Protected health information gathered for this study will be shared 815 
with the coordinating center, the Jaeb Center for Health Research i n Tampa, FL.  De-identified 816 
participant information may also be provided to research sites involved in the study. 817 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 36 OF 50 Chapter 7:  Statistical Consideration s 818 
7.1 Statistical and Analytical Plans  819 
The approach to sample size and statistical analyses are summarized below.  820 
 821 
7.2 Primary  Objective and Hypothes is 822 
The study has one primary objective:  823 
1) To determine if participants with IXT undergoing full -time patching have more 824 
improvement in mean distance control  between baseline and  3 months than participants 825 
being observed without treatment . 826 
 827 
The primary outcome is a comparison of the change in the mean distance control scores (average 828 
of 3 measurements) at [ADDRESS_439088] for Objective # 1 – FT vs OBS  at 3 Months :  833 
 834 
Hnull  FT mean  change  in distance  control  over 3 months  = OBS  mean  change  in distance  control  over 3 months  835 
Halternative   FT mean  change  in distance  control  over 3 months  ≠ OBS  mean  change  in distance  control  over 3 months  836 
 837 
 838 
7.3 Sample Size  839 
Sample size estimation is based on data from our previous IXT2 randomized trial comparing 840 
observation versus part -time patching for intermittent exotropia, limited to 278 participants with 841 
similar baseline age (3 to <9  years ) and baseline control score at distance (2 or higher).22 Data 842 
are summarized in Table 1 below.  843 
  844 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 37 OF 50 Table 1 – Previous IXT2 Randomized Trial Data in 3 - to <9 -Year -Olds  with IXT*  845 
Distance Control Scores* * Cohort  
IXT2  
Glasses Alone  
 
(Observation)  IXT2  
Part -time Patching  
 
(3 hours/Day)  
Baseline    
n 147 131 
Mean (SD)  2.88 (1.01)  2.93 (1.00)  
3-Month Score    
n 131 116 
Mean Score (SD)  2.59 (1.35)  2.15 (1.23)  
95% CI for Mean Score  2.35 to 2.82  1.92 to 2.37 
95% CI for SD Score  1.21 to 1.54  1.09 to 1.41  
3-Month Change from Baseline    
n 131 116 
Mean Change (SD)  0.30 (1.23)  0.78 (1.38)  
95% CI for Mean Change  0.09 to 0.51  0.53 to 1.04  
95% CI for SD Change  1.09 to 1.40  1.22 to 1.59  
*Participants aged 3 to <9 years old with baseline distance control score of 2 or higher (worse).  846 
** A single measure of control was obtained at each visit in the IXT2 study.  847 
 848 
 849 
In IXT2, after 3 months of observation versus treatment with 3  hours per day patching, the 850 
observation group had a mean change based upon a single measure of distance control of 0.30 851 
points  (95% CI , 0.09 to 0.51  points ) with a standard deviation of 1.23 points  (95% CI , 1.09 to 852 
1.40 points ); and the 3  hours per day patching group had a mean change based upon a single 853 
measure of distance control of 0.78 points  (95% CI , 0.53 to 1.04  points ) with a standard 854 
deviation of 1.38 points  (95% CI , 1.22 to 1.59  points ); group difference patching – observation =  855 
0.49 (95% CI 0.16 to 0.81) . The correlation between distance control score at baseline and 856 
change from baseline after 3 months was R=0.39 (95% CI, 0.27 to 0.48).   857 
We are aware of no previous data on distance control score among children with IXT treated 858 
with full-time patching. In our IXT5 study, after 6 months of treatment with overminus 859 
spectacles , the mean change in distance control was 1.40  points  (95% CI , 1.18 to 1.63 points ) [ADDRESS_439089] deviation of 1. 48 points  (95% CI , 1.34 to 1.66 points ). There was no 3 -month 861 
outcome in the IXT5 study; however, in the IXT3 pi[INVESTIGATOR_799], those treated with overminus 862 
spectacles improved on average 1.2 points  (95% CI , 0.5 to 1.9 points ) with a standard deviation 863 
of 1.8 points  (95% CI , 1.4 to 2.5  points ) after 8  weeks. Therefore , we estimate that a mean 864 
change of 1.45 points  after 3 months of full -time patching in the current study is reasonable for 865 
an active treatment.  866 
Sample Size Estimation:  867 
The study will be powered for the primary objective.  868 
Assuming  a mean change in distance control score after 3 months of 0.30 points  in the 869 
observation group and 1.45 points  in the full -time patching group; we estimate that the true [ADDRESS_439090] for Objective  – FT vs OBS  at 3 Months :  [ADDRESS_439091] deviation of 1.5 points  for change in distance control score after 3 874 
months , and a correlation of 0.30 between distance control score at baseline and change from 875 
baseline after 3 months , a total sample size of 68 participants (34 per group) completing the 3 - 876 
month outcome has 90% power with a type I error rate of 5% to evaluate whether there is a 877 
treatment group difference between FT patchin g and OBS if the true difference is 1.15 points , 878 
Table 2. Accounting for 5% loss to follow -up after 3 months, a total of 72 participants ( 36 per 879 
treatment group) will need to be enrolled.  The overall number of participants with an i nterocular 880 
difference in distance VA of 2 logMAR lines (10 letters on E -ETDRS for patients ≥7 years old) will be 881 
limited to 1 4. 882 
Table 2: Total Sample Size for Difference in Mean Distance Control Score  [ADDRESS_439092] Deviation  
of Change in  Distance  
Control ( points ) Treatment Group Difference  for Outcome  of Mean Change in  
Distance Control ( points ) 
0.85 1.00 1.15 
1.4 106 78 60 
1.5 122 90 68 
1.6 138 100 78 
Cells indicate N for the overall study ( two treatment groups combined  with a ratio of 1:1 ), using a [ADDRESS_439093] 80% power to [ADDRESS_439094] the null in favor of a difference  (and 1.05 with 85%).  889 
7.4 Interim Monitoring  890 
Given the short duration of the primary outcome at 3 months, there will be no formal interim 891 
analysis  for stoppi[INVESTIGATOR_352702].  892 
7.5 Analysis Datasets  893 
The primary efficacy analysis will follow an intent -to-treat (ITT) principle. Therefore, the 894 
primary analysis dataset will include all randomized participants with imputation for those 895 
missing the 3 -month outcome  and will analyze them according to the grou p they were originally 896 
assigned . Sensitivity analyses of the primary outcome will follow a modified ITT principle and 897 
use observed data with no imputation for missing outcomes.  898 
7.6 Analysis of the Primary Efficacy Endpoints  899 
The mean of three individual distan ce control scores will be tabulated by [CONTACT_105840] 3 900 
months. The change from baseline in mean control score (mean of three assessments ) will be 901 
compared between the FT patching group and the OBS group at 3 months using an analysis of 902 
covariance (ANC OVA) model that adjust s for the mean distance control score at baseline and [ADDRESS_439095] at baseline . An estimate of difference between the groups will be 904 
reported along with a 95% confidence interval and p -value.   905 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 39 OF 50 When the protocol -specified three measures of control are not performed at the outcome exam, 906 
the mean of two tests will be used for analysis if only 2 distance control tes ts are completed ; the [ADDRESS_439096] an average distance control score imputed using m ultiple imputation . 910 
The multiple imputation will be performed using Monte Carlo Markov Chain (MCMC) modeling 911 
that includes the mean distance control s at the outcome  visit and the following baseline factors : [ADDRESS_439097] .  913 
 Sensitivity Analyses  914 
The f ollowing analyses will be performed as sensitivity analyses  to the primary analysis:   915 
Sensitivity  Analysis #1  (Complete Case Analysis  Including Visits within Analysis Window) :  916 
• All participants  who complete [ADDRESS_439098] s at the 3-month visit  within the 917 
analysis window  (± 1 month)  will have their observed 3-month data analyzed  918 
• Participants  who miss the 3-month visit entirely or who do not complete any control testing 919 
at the 3-month visit within the analysis window will be excluded from the analysis  920 
Sensitivity  Analysis # 2 (Complete Case Analysis Including Visits within Protocol  Window) :  921 
• Repeat the above sensitivity analysis using observed data from participants who completed 922 
the 3-month visit within the protocol window (± 2 weeks).   923 
 924 
Sensitivity Analysis #3 (ITT minus participants with IOD 2 logMAR lines at enrollment):  925 
• The overall number of participants with an i nterocular difference in distance VA of 2 926 
logMAR  lines (10 letters on E -ETDRS for patients ≥7 years old) will be limited to 1 4. 927 
• The ITT analyses as described in 7.5 will be repeated excluding these participants.  928 
 929 
7.7 Analysis of the Secondary Endpoints  930 
All se condary analyses described below will use observed data only.  Treatment group 931 
comparisons specified in the sections below will be controlled using false discovery rate (FDR)  932 
at the 5% probability level  to account for the multipl e outcomes . For all secondary analyses, an [ADDRESS_439099] - 934 
adjusted confidence interval and p -value  unless otherwise specified . Further details about the 935 
secondary analyses below will be p art of a separate statistical analysis plan (SAP).  936 
 Near Control  937 
At 3 months , near control will be evaluated similarly to the distance control primary analysis 938 
(section 7.6) using ANCOVA models that adjust for the mean near control score at baseline  and [ADDRESS_439100]’s [ADDRESS_439101]/retest variability63 will be compared between the treatment groups at [ADDRESS_439102]’s test with calculation of a two -sided FDR -adjusted confidence interval on 952 
the difference in proportions.  953 
 Level of Suppression  954 
The proportion with each level of  suppression (negligible, mild, moderate, or dense) will be [ADDRESS_439103]’s test for the difference in proportions.  960 
 Convergence and Divergence Fusional Amplitudes  961 
The distribution of fusional convergence amplitude ( blur point, b reak point, and recovery) and 962 
fusional divergence amplitude (break point and recover y point) will be described and compared [ADDRESS_439104].  When no blur is 964 
reported for fusion convergence, the break point will be used for analysis.  965 
 IXT Symptom Survey Score  966 
The IXT Symptom  Survey  will be completed by [CONTACT_352735] 3-month exam s. 967 
The distribution for each individual item (‘Never’, ‘Sometimes’, ‘All the Time) will be tabulated 968 
for each treatment group  within subgroups defined by [CONTACT_654] 5 to 9  years  (all items) and age <5  969 
years  for the single diplopia question . 970 
 PedEyeQ Score  971 
The PedEy eQ consists of 3 components: child, proxy, and parent. After applying existing Rasch [ADDRESS_439105] -adjusted  confidence 975 
interval will be calculated.  976 
 Binocular Diplopia by [CONTACT_352705]  977 
The proportion of  binocular diplopia at 3 months with a frequency of “more than 2 times per 978 
day” over the last week at distance or near,  by [CONTACT_352736] s [ADDRESS_439106]’s test . 980 
 981 
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 41 OF 50 7.8 Exploratory Analyses  982 
Exploratory analyses described below will use observed data only. Point estimates and 95% CIs 983 
will be reported for each outcome with no adjustment for multiplicity.   984 
 Actual Patch Wear Time  985 
The distribution of actual patch wear time will be tabulated  overall and by [CONTACT_6660]. The 986 
potential correlation between actual patch wear time in the FT patching group and the change 987 
from baseline in the following outcomes will be evaluated at 3 months (when collected):  988 
1. Distance control score  989 
2. Near control  score  990 
3. Distance angle of deviation  991 
4. Near angle of deviation  992 
5. Level of suppression  993 
6. Convergence fusional amplitudes  994 
7. Divergence fusional amplitudes  995 
8. Symptom survey score  996 
9. Diplopia assessment by [CONTACT_85189]  997 
10. PedEyeQ score  (each domain)  998 
A Spearman correlation coefficient and 95% confidence interval will be calculated  for each [ADDRESS_439107] to the following outcomes 1002  
within each treatment group will be evaluated at 3 months:  1003  
1. Distance control score  1004  
2. Near control  score  1005  
3. Distance angle of deviation  1006  
4. Near angle of deviation  1007  
5. Level of suppression  1008  
6. Convergence fusional amplitudes  1009  
7. Divergence  fusional amplitudes  1010  
8. Symptom survey score  1011  
9. Diplopia assessment by [CONTACT_85189]  1012  
10. PedEyeQ score  1013  
For continuous outcome variable s, the difference in means between participants with normal 1014  
versus anomalous retinal correspondence will be calculated along with a 95% con fidence 1015  
interval. For categorical outcome variables, the difference in proportions between participants  1016  
with normal versus anomalous  retinal correspondence will be calculated along with a 95% 1017  
confidence interval .  1018  
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 42 OF 50 
 Subgroup  Analysis of Distance Control  1019  
The treatment group comparison of distance control will be assessed at 3 months in subgroups 1020  
based on gender and race/ethnicity in accordance with NIH guidelines; however, no effect 1021  
modification is expected for these factors.  1022  
 1023  
7.9 Safety Analyses  1024  
 1025  
 Deterioration  1026  
The number and proportion  of participants with deterioration, as defined below , will be tabulated 1027  
for each treatment group at 3 months  as a safety outcome.  1028  
Deterioration is defined as meeting one of the following criteria at  the 3 months follow -up visit:  [ADDRESS_439108]:  1031  
o Constant is defined as an exotropia present throughout the examination and 1032  
confirmed  by [CONTACT_352727]/uncover test ing performed at least 3 different times over the 1033  
course of  the exam  (including during assessment of IXT control) . [ADDRESS_439109] . 1036  
 Reduction of Distance Visual Acuity  1037  
Any cases of 1) interocular di fference ≥0.3 logMAR and 2) reduced visual acuity in best 1038  
refractive correction (≥0.3 logMAR) in either eye will be tabulated by [CONTACT_105840] 3 1039  
months . 1040  
 Diplopia  1041  
After 3 months, a ny new cases of diplopia  ‘Sometimes’ or ‘All the Time’ , based on response  to 1042  
item 8  from the IXT symptom survey  (asked as a single question for children ages 3 and 4 years 1043  
of age)  will be tabulated for each treatment group. In addition, diplopia occurring ‘Never’, 1044  
‘Sometimes’, or  ‘All the Time’  will also be tabulated for each treatment group.  1045  
 1046  
7.10 Patching  Adherence  1047  
Patching adherence  (as reported by [CONTACT_7071])  will be tabulated at the 3 -month visit for the FT 1048  
patching treatment group, as will reasons for any major deviations.  1049  
7.11 Additional Tabulations and Analyses  1050  
The following tabulations and analyses will be performed:  1051  
• A flow chart accounting for all participants according to treatment group  1052  
• Visit completion rates according to treatment group  1053  
• Baseline demographics a nd clinical characteristics overall and by [CONTACT_105840] 1054  
randomization  1055  
• Protocol deviations according to treatment group   1056  
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 43 OF 50 Chapter 8:  Data Collection and Monitoring  1057  
8.1 Case Report Forms and Other Data Collection  1058  
The main study data are collected on electronic case report forms (CRFs). When data are directly 1059  
collected in electronic case report forms, this will be considered the source data. For any data 1060  
points for which the eCRF is not considered source (e.g., lab results that are transcribed from a 1061  
printed report into the eCRF), the original source documentation must be maintained in the 1062  
participant’s study chart or medical record. This source must be readily verifiable against the [ADDRESS_439110] be recorded (e.g., office note, visit [ADDRESS_439111], etc.) . 1066  
Electronic device data files are obtained from the study software and individual hardware 1067  
components.  These electr onic device files are considered the primary source documentation.  1068  
Each participating site will maintain appropriate medical and research records for this trial, in 1069  
compliance with ICH E6 and regulatory and institutional requirements for the protection of 1070  
confidentiality of participants.  1071  
 1072  
8.2 Study Records Retention  1073  
Study documents should be retained for a minimum of 3 years after completion of the final grant 1074  
reporting . These documents should be retained for a longer period, however, if required by [CONTACT_5737] 1075  
regul ations.  No records will be destroyed without the written consent of the sponsor, if 1076  
applicable.  It is the responsibility of the sponsor to inform the investigator when these documents 1077  
no longer need to be retained.  1078  
 1079  
8.3 Quality Assurance and Monitoring  1080  
Designa ted personnel from the Coordinating Center will be responsible for maintaining quality 1081  
assurance (QA) and quality control (QC) systems to ensure that the clinical portion of the trial is 1082  
conducted and data are generated, documented and reported in complian ce with the protocol 1083  
adhering to Good Clinical Practice (GCP) and the applicable regulatory requirements, as well as 1084  
to ensure that the rights and wellbeing of trial participants are protected and that the reported trial 1085  
data are accurate, complete, and ve rifiable.  Adverse events will be prioritized for monitoring.  1086  
A risk -based monitoring (RBM) plan will be developed and revised as needed during the course 1087  
of the study, consistent with the FDA “Guidance for Industry Oversight of Clinical 1088  
Investigations — A Risk-Based Approach to Monitoring” (August 2013).  This plan describes in [ADDRESS_439112] importance for monitoring at the site are participant eligibility and adverse 1092  
events.  Therefore, the RBM plan will focus on these areas.  As much as possible, remote 1093  
monitoring will be performed in real -time with on -site monitoring performed to evaluate the 1094  
verity and completeness of the key site data.   1095  
  1096  
JAEB CENTER FOR HEALTH RESEARCH  
IXT7P ROTV1.0_19A PR2022 PAGE 44 OF 50 Elements of the RBM may include:  1097  
• Qualification assessment, training, and certification for sites and site personnel  1098  
• Oversight of Institutional Review Board (IRB) coverage and informed consent 1099  
procedures  1100  
• Central (remote) data monitoring: validation of data entry, data edits/audit trail, protocol 1101  
review of entered data and edits, statistical monitoring, study closeout  1102  
• On-site monitoring (site visits): source data verification, site visit report  1103  
• Agent/Device accountability  1104  
• Communications with site staff  1105  
• Patient retention and visit completion  1106  
• Quality control reports  1107  
• Management of noncompliance  1108  
• Documenting monitoring activities  1109  
• Adverse event reporting and monitoring  [ADDRESS_439113] access to all trial related sites, source 1114  
data/documents, and reports for the purpose of monitoring and auditing by [CONTACT_456], and 1115  
inspection by [CONTACT_3482].  1116  
 1117  
8.4 Protocol Devia tions  1118  
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or procedure 1119  
requirements.  The noncompliance may be either on the part of the participant, the investigator, or 1120  
the study site staff.  As a result of deviations, correcti ve actions are to be developed by [CONTACT_779] 1121  
and implemented promptly.  1122  
The site PI/study staff is responsible for knowing and adhering to their IRB requirements.  1123  
Further details about the handling of protocol deviations will be included in the monitoring pla n. 1124  
 
IXT7P ROTV1.0_19A PR2022 PAGE 45 OF 50 Chapter 9:   Ethics/Protection of Human Participants  [ADDRESS_439114]  1126  
The investigator will ensure that this study is conducted in full conformity with Regulations for 1127  
the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 1128  
21 CFR Part 56, and/or the ICH E6.  1129  
 1130  
9.2 Institutional Review Boards  1131  
The protocol, informed consent form(s), recruitment materials, and all participant materials will [ADDRESS_439115] be obtained before any participant is enrolled.  Any amendment to the protocol will 1134  
require review and approval by [CONTACT_3484].  All 1135  
changes to the consent form will be IRB approved; a determination will be made regarding 1136  
whether previously consented participants need to be re -consented.  1137  
 1138  
9.3 Informed Consent Process  1139  
 Consent Procedures  and Documentation  1140  
Informed consent is a process that is initiated prio r to the individual’s agreeing to participate in 1141  
the study and continues throughout the individual’s study participation.  Extensive discussion of [ADDRESS_439116] by [CONTACT_352737], their staff, 1158  
and the sponsor(s) and their agents. This confidentiality is extended to cover testing of biological [ADDRESS_439117] all documents and records 1165  
required to be maintained by [CONTACT_093], including but not limited to, medical records 1166  
 
IXT7P ROTV1.0_19A PR2022 PAGE 46 OF 50 (office , clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study.  The clinical 1167  
study site will permit access to such records.  1168  
The study participant’s contact [CONTACT_3487] [ADDRESS_439118] atistical analysis and scientific 1173  
reporting, will be transmitted to and stored at the Jaeb Center for Health Research.  This will not 1174  
include the participant’s contact [CONTACT_1290].  Rather, individual participants and [ADDRESS_439119] access to research records to refuse to 1183  
disclose identifying information on research participation in any civil, criminal, administrative, 1184  
legislative, or other proceeding, whether at t he federal, state, or local level.  By [CONTACT_263254] 1185  
researchers and institutions from being compelled to disclose information that would identify 1186  
research participants, Certificates of Confidentiality help achieve the research objectives and 1187  
promote participa tion in studies by [CONTACT_4205][INVESTIGATOR_21783].  1188  
 Future Use of Data  1189  
Data collected for this study will be analyzed and stored at the Jaeb Center for Health Research.  1190  
After the study is completed, the de -identified, archived da ta will be made available to the 1191  
public.  1192  
 
IXT7P ROTV1.0_19A PR2022 PAGE 47 OF 50 Chapter 10:  References  1193  
1. Govindan M, Mohney BG, Diehl NN, Burke JP. Incidence and types of childhood 1194  
exotropia: A population -based study. Ophthalmology. 2005;112(1):104 -108. 1195  
2. Friedman DS, Repka MX, Katz J, et al. Prevalence of amblyopia and strabismus in white 1196  
and African Americ an children aged 6 through 71 months. The Baltimore Pediatric Eye 1197  
Disease Study. Ophthalmology. 2009;116(11):2128 -2134.  1198  
3. Nusz KJ, Mohney BG, Diehl NN. Female predominance in intermittent exotropia. Am J 1199  
Ophthalmol. 2005;140(3):[ADDRESS_439120] Ophthalmol Vis Sci. 2010;51(7):3411 -3417.  1202  
5. Chia A, Roy L, Seenyen L. Comitant horizontal strabismus: an Asian perspective. Br J 1203  
Ophthalmol. 2007;91(10 ):1337 -1340.  1204  
6. McKean -Cowdin R, Cotter SA, Tarczy -Hornoch K, et al. Prevalence of amblyopia or 1205  
strabismus in Asian and non -Hispanic white preschool children: Multi -ethnic Pediatric 1206  
Eye Disease Study. Ophthalmology. 2013;120(10):2117 -2124.  1207  
7. Costenbader F . The physiology and mangement of divergent strabismus. In: Allen JH, ed. [ADDRESS_439121]. Louis: Mosby [CONTACT_352738]; 1950:353.  [ADDRESS_439122]. Comparative measurement of exodeviations at twenty and one 1210  
hundred feet. Trans Am Ophth almol Soc. 1971;69:188 -199. 1211  
9. Cooper J. Intermittent exotropia of the divergence excess type. J Am Optom Assoc. 1212  
1977;48(10):1261 -1273.  1213  
10. Campos EC, Cipolli C. Binocularity and photophobia in intermittent exotropia. Percept 1214  
Mot Skills. 1992;74(3 pt 2):1168 -1170.  1215  
11. Wang FM, Chryssanthou G. Monocular eye closure in intermittent exotropia. Arch 1216  
Ophthalmol. 1988;106(7):941 -942. 1217  
12. Wiggins RE,  von Noorden GK. Monocular eye closure in sunlight. J Pediatr Ophthalmol 1218  
Strabismus. 1990;27(1):16 -20. 1219  
13. Hatt SR, Leske DA, Mohney BG, Brodsky MC, Holmes JM. Classification and 1220  
misclassification of sensory monofixation in intermittent exotropia. Am J Oph thalmol. 1221  
2010;150(1):[ADDRESS_439123] 1223  
Rev. 2013(5):Art. No.: SAHA02.  1224  
15. Pratt -Johnson JA, Barlow JM, Tillson G. Early surgery in intermittent exotropia. Am J 1225  
Ophthalmol. 1977;8 4(5):689 -694. 1226  
16. Cooper J, Medow N. Intermittent exotropia, basic and divergence excess type. Binocular 1227  
Vision & Strabismus Quarterly. 1993;8(3):[ADDRESS_439124] Ophthalmol Vis Sci. 1230  
2011;52(5):[ADDRESS_439125] CD. Suppression and retinal correspondence in intermittent exotropia. 1232  
Br J Ophthalmol. 1986;70(9):673 -676. 1233  
19. Cooper J, Feldman J. Panoramic vie wing, visual acuity of the deviating eye, and 1234  
anomalous retinal correspondence in the intermittent exotrope of the divergence excess 1235  
type. Am J Optom Physiol Opt. 1979;56(7):422 -429. 1236  
 
IXT7P ROTV1.0_19A PR2022 PAGE 48 OF 50 20. Romano PE, Wilson MF. Survey of current management of intermittent ex otropia in the 1237  
[LOCATION_003] and Canada. In: Campos EC, ed. Strabismus and Ocular Motility Disorders.  1238  
London: The Macmillan Press; 1990:391 -396. 1239  
21. Barnett -Itzhaki G, Friehmann A, Barnett -Itzhaki Z, Ela -Dalman N. Diagnosis and 1240  
Management Practice Patterns among Ped iatric Ophthalmology Personnel in Israel. J 1241  
Binocul Vis Ocul Motil. 2019;69(1):34 -41. 1242  
22. Pediatric Eye Disease Investigator Group. A randomized trial comparing part -time 1243  
patching with observation for children 3 to 10 years of age with intermittent exotrop ia. 1244  
Ophthalmology. 2014;121(12):2299 -2310.  1245  
23. Pediatric Eye Disease Investigator Group. A randomized trial comparing part -time 1246  
patching with observation for intermittent exotropia in children 12 to 35 months of age. 1247  
Ophthalmology. 2015;122(8):1718 -1725.  1248  
24. Mohney BG, Cotter SA, Chandler DL, et al. Three -year observation of children 3 to 10 1249  
years of age with untreated intermittent exotropia. Ophthalmology. 2019;126(9):1249 - 1250  
1260.  1251  
25. Holmes JM, Hercinovic A, Melia BM, et al. Health -related quality of life i n children with 1252  
untreated intermittent exotropia and their parents. J AAPOS. 2021;25(2):80.e81 -80.e84.  1253  
26. Cotter SA, Mohney BG, Chandler DL, et al. Three -year observation of children 12 to 35 1254  
months old with untreated intermittent exotropia. Ophthalmic Ph ysiol Opt. 1255  
2020;40(2):[ADDRESS_439126] active monitoring for 1258  
childhood intermittent exotropia [X(T)]. Health  Technol Assess. 2015;19(39):[ADDRESS_439127] for basic -type intermittent exotropia. 1261  
Ophthalmology. 2019;126(2):305 -317. 1262  
29. Kushner BJ. Selective surgery for intermittent exotropia based on distance/near 1263  
differences. Arch Ophthalmol. 1998;116(3):324 -328. 1264  
30. Repka MX, Chandler DL, Holmes JM, et al. The Relationship of Age and Other Baseline 1265  
Factors to Outcome of Initial Surgery for Intermittent Exotropia. Am J Ophthalmol. 1266  
2020;212:153 -161. 1267  
31. Chen AM, Erzurum SA, Chandler DL, et al. Overminus lens therapy for  children 3 to 10 1268  
years of age with intermittent exotropia: A randomized clinical trial. JAMA Ophthalmol. 1269  
2021;139(4):464 -476. 1270  
32. Flynn JT, McKenney S, Rosenhouse M. Management of intermittent exotropia. In: 1271  
Moore S, Mein J, Stockbridge L, eds. Orthoptics : Past, Present, Future.  Chicago: Year 1272  
Book Medical Publishers; 1976:551 -557. 1273  
33. Iacobucci I, Henderson JV. Occlusion in the preoperative treatment of exotropia. Am 1274  
Orthopt J. 1965;15:42 -47. 1275  
34. Akbari MR, Mehrpour M, Mirmohammadsadeghi A. The influence o f alternate part -time 1276  
patching on control of intermittent exotropia: a randomized clinical trial. Graefes Arch 1277  
Clin Exp Ophthalmol. 2021;259(6):1625 -1633.  1278  
35. Mohney BG, Holmes JM. An office -based scale for assessing control in intermittent 1279  
exotropia. Strabismus. 2006;14(3):147 -150. 1280  
36. Coffey B, Wick B, Cotter S, Scharre J, Horner D. Treatment options in intermittent 1281  
exotropia: a critical appraisal. Optom Vis Sci. 1992;69(5):386 -404. 1282  
 
IXT7P ROTV1.0_19A PR2022 PAGE 49 OF 50 37. Heydarian S, Hashemi H, Jafarzadehpour E, et al. Non -surgical managem ent options of 1283  
intermittent exotropia: A literature review. J Curr Ophthalmol. 2020;32(3):217 -225. 1284  
38. AlKahmous LS, Al -Saleh AA. Does occlusion therapy improve control in intermittent 1285  
exotropia? Saudi Journal of Ophthalmology. 2016;30(4):240 -243. 1286  
39. Kush ner BJ. Conservative management of intermittent exotropia to defer or avoid 1287  
surgery. J AAPOS. 2019;23(5):256.e251 -256.e256.  1288  
40. Jampolsky A. Physiology of intermittent exotropia. Am Orthopt J. 1963;13:5 -13. 1289  
41. Pratt -Johnson J, Wee HS. Suppression associat ed with exotropia. Can J Ophthalmol. 1290  
1969;4(2):136 -144. 1291  
42. Cooper J, Feldman J, Pasner K. Intermittent exotropia: stimulus characteristics affect 1292  
tests for retinal correspondence and suppression. Binocul Vis Strabismus Q. 1293  
2000;15(2):[ADDRESS_439128] for objective 1295  
assessment of sensorial status in intermittent exotropia. Eur J Ophthalmol. 2000;10(1):[ADDRESS_439129] of suppression 1298  
during tr opia and phoria on phoria maintenance in intermittent exotropia. Graefes Arch 1299  
Clin Exp Ophthalmol. 2013;251(10):2463 -2469.  1300  
45. Hatt SR, Leske DA, Mohney BG, Brodsky MC, Holmes JM. Fusional convergence in 1301  
childhood intermittent exotropia. Am J Ophthalmol. 2011;152:314 -319. 1302  
46. Liebermann L, Hatt SR, Leske DA, et al. Assessing divergence in children with 1303  
intermittent exotropia. Strabismus. 2012;20(1):11 -16. 1304  
47. Chutter CP. Occlusion treatment of intermittent divergent strabismus. Am Orthopt J. 1305  
1977;27:80 -84. 1306  
48. Vishnoi SK, Singh V, Mehra MK. Role of occlusion in treatment of intermittent 1307  
exotropia. Indian J Ophthalmol. 1987;35(4):207 -210. 1308  
49. Spoor DK, Hiles DA. Occlusion therapy for exodeviations occurring in infants and young 1309  
children. Ophthalmology. 1979;8 6(12):2152 -2157.  1310  
50. Bang SP, Lee DC, Lee SY. Surgical outcome of intermittent exotropia with improvement 1311  
in control grade subsequent to part -time preoperative occlusion therapy. J Pediatr 1312  
Ophthalmol Strabismus. 2018;55(1):59 -64. 1313  
51. Wang J, Xu H, De La Cr uz B, et al. Improved monitoring of adherence with patching 1314  
treatment using a microsensor and Eye Patch Assistant. J AAPOS. 2020;24(2):94.e91 - 1315  
94.e97.  1316  
52. Fielder AR, Irwin M, Auld R, Cocker KD, Jones HS, Moseley MJ. Compliance in 1317  
amblyopia therapy: objecti ve monitoring of occlusion. Br J Ophthalmol. 1995;79(6):585 - 1318  
589. 1319  
53. Stewart CE, Stephens DA, Fielder AR, Moseley MJ, ROTAS Cooperative. Objectively 1320  
monitored patching regimens for treatment of amblyopia: randomised trial. Br Med J. 1321  
2007;335(7622):707 -713. 1322  
54. Loudon SE, Passchier J, Chaker L, et al. Psychological causes of non -compliance with 1323  
electronically monitored occlusion therapy for amblyopia. Br J Ophthalmol. 1324  
2009;93(11):1499 -1503.  1325  
55. Holmes JM, Hercinovic A, Melia BM, et al. Health -related quality  of life in children with 1326  
untreated intermittent exotropia and their parents. J AAPOS. 2021.  1327  
 
IXT7P ROTV1.0_19A PR2022 PAGE 50 OF 50 56. Drover JR, Felius J, Cheng CS, Morale SE, Wyatt L, Birch EE. Normative pediatric 1328  
visual acuity using single surrounded HOTV optotypes on the Electronic Visual Acuity 1329  
Tester following the Amblyopia Treatment Study protocol. J AAPOS. 2008;12(2):145 - 1330  
149. 1331  
57. Pan Y, Tarczy -Hornoch K, Cotter SA, et al. Visual acuity norms in pre -school children: 1332  
the Multi -Ethnic Pediatric Eye Disease Study. Optom Vis Sci. 2009;86(6):[ADDRESS_439130] RM, Donohoe N, Leske DA, Birch EE. Normative 1334  
pediatr ic visual acuity using electronic Early Treatment for Diabetic Retinopathy protocol 1335  
J AAPOS. 2021;25(3):172 -175. 1336  
59. Hatt SR, Leske DA, Holmes JM, et al. Testing depth of suppression in childhood 1337  
intermittent exotropia. J aapos. 2021.  1338  
60. Bielschowsky A. D ivergence excess. Arch Ophthalmol. 1934;12(2):157 -166. 1339  
61. Hatt SR, Leske DA, Castañeda YS, et al. Development of pediatric eye questionnaires for 1340  
children with eye disease. Am J Ophthalmol. 2019;200:[ADDRESS_439131] on health -related quality of life. Strabismus. 2016;24(4):139 - 1343  
145. 1344  
63. Hatt SR, Leske DA, Liebermann L, Mohney BG, Holmes JM. Variability of angle of 1345  
deviation measurements in children with  intermittent exotropia. J AAPOS. 1346  
2012;16(2):120 -124. 1347  
 1348  